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ABSTRACT 
INVESTIGATING EVOLUTIONARY TRADE-OFFS FOR DESIGNING NOVEL 
STRATEGIES TO SLOW DOWN EVOLUTION OF ANTIBIOTIC RESISTANCE 
 
 
Tuğçe Öz 
Biological Sciences and Bioengineering Program, Sabanci University, 
MSc. Thesis, 2013 
Thesis supervisor: Erdal Toprak 
 
Keywords: Antibiotics, Antibiotic Resistance, Cross Resistance, Phenotype, 
Genotype, Whole Genome Sequencing, Mutation 
  
Antibiotic resistance is a global public health problem. The straightforward solution 
to this problem is developing new antibiotics that can kill all of the drug resistant bugs, 
alas; this has not been possible so far due to economic and natural limitations. Another 
plausible solution to this problem is the effective use of already existing antibiotics by 
designing novel treatment strategies. However, efforts towards finding such strategies have 
not been rewarding to the date due to our limited knowledge about the origins of antibiotic 
resistance at the molecular and population levels. In order to tackle this problem, we 
performed an extensive laboratory evolution experiment where we evolved drug sensitive 
E.coli populations against 22 different clinically important antibiotic compounds and 
systematically phenotyped and genotyped evolved populations. Benefiting from this 
extensive data set, we identified common genetic targets for resistance conferring mutations 
and resulting phenotypic changes. Our analysis allows us design effective multidrug 
treatments strategies that can slow down evolution of antibiotic resistance. We hope that, 
the methodologies that were developed throughout this study will also be helpful for 
finding effective therapies for combating cancer and immune disease.  
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ÖZET 
 
EVRĐMSEL ÖDÜNLEŞĐMLERĐN ARAŞTIRILARAK ANTĐBĐYOTĐK DĐRENCĐNĐ 
YAVAŞLATMAK ĐÇĐN YENĐ STRATEJĐLERĐN BELĐRLENMESĐ 
 
 
Tuğçe ÖZ 
Biyoloji Bilimleri ve Biyomühendislik Programı, Sabancı Üniversitesi, 
Master Tezi, 2013 
Tez Danışmanı: Erdal Toprak 
 
Anahtar Kelimeler: Antibiyotik, Antibiyotik Direnci, Çapraz Direnç, Fenotip, Genotip, 
Tüm Genom Dizilemesi, Mutasyon 
Antibiyotik direnci küresel bir halk sağlığı sorunudur. Bu problemin en kolay 
çözümü tüm dirençli bakterileri öldürebilecek yeni ilaçlar geliştirmektir ama ne yazık ki bu 
çözüm ekonomik ve doğal kısıtlamalar sebebiyle mümkün olmamaktadır. Bir başka makul 
çözüm de alternatif tedavi metotları geliştirerek mevcut ilaçların daha etkili kullanılmasıdır. 
Henüz yeni strateji belirleme çabaları moleküler ve popülasyon düzeyinde antibiyotik 
direncinin sebepleri hakkındaki bilginin kısıtlı olması yüzünden faydalı olamamıştır. Biz bu 
sorunu çözmek için, ilaca duyarlı E.coli bakterilerilerini 22 farklı klinik olarak önemli 
antibiyotiğe karşı direnç kazandırdığımız ve sistematik olarak fenotip ve genotip 
değişikliklerine baktığımız geniş bir evrim deneyi uyguladık. Dirence sebep olan 
mutasyonların ortak genetik hedefleri ve neden olduğu fenotipik değişiklikleri 
oluşturduğumuz geniş veri setimizden faydalanarak belirledik. Analizlerimizi kullanarak 
antibiyotik direnci miktarını azaltabileceğimiz, çoklu ilaç tedavi stratejileri belirleyebiliriz. 
Umuyoruz ki bu araştırmayla geliştirdiğimiz yöntemler, kanser ve bağışıklık sistemi 
hastalıklarına karşı etkili tedavi bulmada da yardımcı olacaktır. 
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1. INTRODUCTION
1.1 Antibiotics 
1.1.1 General Overview 
 
The  discovery  of  penicillin  by  Alexander  Fleming  is  a  milestone  in  modern  
medicine  because  it  saved  millions  of  human  and  animal  lives  by  curing  previously  
untreatable  microbial  diseases.  Antibiotics  are  nanometer-sized  small  molecules  that  can  
cure bacterial infections by killing bacteria or inhibiting their growth. Antibiotics in nature  
are mostly produced by microorganisms Wi.e. actinomycetes, streptomyces, and fungiS and  
although  there  is  no  direct  evidence,  natural  antimicrobial  products  are  conventionally  
considered  to  be  secondary  metabolites  that  have  roles  in  microbial  communication.  
Biological  and  ecological  roles  of  antibiotics  are  yet  poorly  understood,  for  example,  
antibiotic producing bacteria often secrete antibiotic molecules that have inhibitory effects  
on  their  competitors  after  forming  spores  as  a  result  of  starvation,  when  there  is  no  
competition  for  resources[1].Although  several  synthetic  antibiotic  molecules  exist  as  of  
today, the majority of the clinically relevant antibiotics are derived from nature and further  
modified for higher efficacy and lower toxicity [1, 2]. With the advances in chemistry and  
structural biology, novel clinically important antibiotics were produced solely by chemical  
synthesis.  Sulfonamides, quinolones  and oxazolidinones  are  examples  of  synthetic  
antibiotics[2]. 
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1.1.2 Mechanism of Action of Antimicrobial Agents 
 
 
Antibiotics can be grouped into two main classes: bacteriostatic and bactericidal. 
Bacteriostatic antibiotics inhibit growth or proliferation of bacteria. This way, they give 
time to the immune system of host forremoving the infecting microorganisms from the 
body. Hence, complete removal of bacteria depends on strength of the immune system[3]. 
On the other hand, bactericidal antibiotics can kill bacteria when used in appropriate doses 
usually by breaking cell wall integrity. That being said, differentiating bacteriostatic and 
bactericidal antibiotics is not always possible because high concentrations of some 
bacteriostatic agents can also have bactericidal effects. Likewise,low concentrations of 
some bactericidal agents have bacteriostatic effects[4]. 
 
 
1.1.3 Major Antibiotic Classes 
The mechanism of action of antibiotics is categorized based on the physiological 
functions affected in the presence ofdrugs or the structure of the bacteria. There are four 
major targets in bacterial pathogens according to mode of antibiotic action: cell wall 
biosynthesis, protein synthesis, DNA replication and repair, and folate metabolism[1]. 
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Figure1.1 Major targets for antibacterial action: DNA replication, protein synthesis, cell 
wall biosynthesis and folic acid biosynthesis are main targets for antibiotics. Protein 
synthesis is mainly blocked by 50S and 30S subunits binding inhibitors. In folic acid 
metabolism, dihydrofolate (DHF) reductase enzyme is blocked and formation of 
tetrahydrofolate (THF) is inhibited. 
1.1.3.1 Cell Wall Biosynthesis Inhibitors 
Gram staining is a method to differentiate bacterial species into two large groups, 
namely gram-negative and gram-positive, according to the chemical and physical properties 
of their cell walls by detecting peptidoglycan (PG) layer in the cell wall. Gram-negative 
and gram-positive bacteria both have PG layers as part of cell wall structure but gram-
positive bacteria have thicker and multilayered PG layers, as shown in Figure 1.2. When 
these layers are corrupted by antibiotics or other chemicals, cells lyse and die consequently. 
Therefore, such cell wall structures are good targets for antibiotic therapies. The other 
difference between gram positive and gram negative bacteria is the existence of the second 
outer membrane in gram negative bacteria; hence, gram-positive bacteria are susceptible to 
some antibiotics that do not work against gram-negative bacteria because of the limited 
pore sizes of porin proteins of the gram-negative microorganisms’ outer membrane[1]. 
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Figure 1.2 The cell wall structures in gram positive and gram negative bacteria. Gram 
positive bacteria have thicker peptidoglycan layer and gram negative bacteria have a second 
outer membrane. 
Peptidoglycan, also known as murein, is a polymer consisting two hexoses: N-
acetylglucosamine (GlcNac) and N-acetyl-muramic acid (MurNAc). The biochemicalsteps 
of peptidoglycan biosynthesis are catalysed by the enzymes MurA–F and MurG. Then, 
peptidoglycan units are transferred to the cell membrane by lipid-bactoprenol-phosphate for 
generating lipids I and II. Sugars and phosphates are added by transglycosylation and 
pyrophosphorylation, and finally, a peptide bond between the peptide chains is 
formed[5]. Several transpeptidases and transglycosylases connect the newly formed 
peptidoglycan structures to the cell wall peptidoglycan matrix[6]. All of these steps are 
targets for antibiotics, as shown in Fig.1.3. Specific antibiotics interfere with the synthesis 
of the cell wall, weakening the peptidoglycan scaffold within the bacterial wall so that the 
structural integrity eventually fails. For example, beta- lactams are bactericidal antibiotics 
that inhibit transpeptidase enzymes and prevent the assembly of the peptidoglycan layer in 
both Gram-positive and Gram-negative bacteria. Fosfomycin and tunicamycin inhibit 
MurA ang Mur G, respectively[5]. 
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Figure 1.3 Targets for cell wall biosynthesis: Murein biosynthesis pathway is an important 
target for antibiotics. Fosfomycin blocks MurA in the first step. Penicillins and 
cephalosporin inhibit transpeptidases, adapted from reference [5]. 
 
β-Lactam antibiotics are  broad class of antibiotics, which contain a β-lactam ring in 
their molecular structures. Some of β-Lactams are penicillin derivatives 
(penams), cephalosporins (cephems), monobactams, and carbapenems. Chemical structures 
of these antibiotics are shown in Figure 1.4. 
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Figure 1.4 Chemical structures of beta-lactam antibiotics[1] 
 
Vancomycin and teicoplanin, known as glycopeptide antibiotics, also prevent cell 
wall construction by interfering with transglycosylases steps. Their effectiveness is limited 
to Gram-positive bacteria because they cannot penetrate the outer membrane of Gram-
negative bacteria due to their very large sizes. Size differences between different cell wall 
inhibitor antibiotics are demonstrated in Figures 1.4 and 1.5. When used in therapies, β-
lactams selectively targets the infecting bacteria with almost no significant effect on the 
cells of the mammalian host since mammalian cells have a plasma membrane but lack the 
peptidoglycan wall structure[6]. 
 
 
 
 
  
 
 
 
1.1.3.2 Protein Synthesis Inhibitors
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Figure 1.6 Crystal Structure of ribosome[8] 
 
Antibiotics that block bacterial protein biosynthesis are often grouped as 30S 
subunit binding and 50S binding ribosomal inhibitors. 30S binding ribosomal inhibitors 
include aminoglycosides and tetracycline antibiotics. Tetracyclines, including doxycycline, 
prevent binding of aminoacyl-tRNA by blocking the A (aminoacyl) site of the 30S subunit 
of the ribosome. Aminoglycoside antibiotics, translation initiation inhibitors, have an 
affinity for the 30S subunit of the ribosome. Streptomycin, one of the most commonly used 
aminoglycosides in the clinic, interferes with the formationof the ribosomal 30S initiation 
complex.  Kanamycin and tobramycin, the other two commonly used aminoglycosides, also 
bind to the 30S subunit of the ribosome and block the formation of the larger 70S initiation 
complex[9]. 50S binding ribosomal inhibitors include oxazolidinones, inhibitors of peptidyl 
transferases (amphenicols and pleuromutulins), macrolides, lincosamides, and 
streptogramins (shortly MLS) antibiotics. The inhibitory mechanism of oxazolidinones 
relies on targeting an early step involving the binding of N-formylmethionyl-tRNA to the 
ribosome[7]. Chloramphenicol, another ribosomal inhibitor, binds residues on the 23S 
rRNA (ribosomal RNA) of the ribosome and inhibits peptide bond formation 
[10].Macrolides inhibit ribosomal translocation by preventing peptidyl transferase[1, 9]. 
Some of the protein synthesis inhibitors and how they interfere with the translation process 
are demonstrated in Figure 1.7.  
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Figure 1.7 Antibiotics acting on the translational machinery.50S and 30S subunits 
of 70S prokaryotic ribosome and action of different antibiotics on protein synthesis is 
indicated in the figure. Chloramphenicol binds to 50S r-RNA and inhibits formation of 
peptide bond, streptomycin changes the shape of 30S portion and tetracyclines interfere 
with attachment of tRNA to mRNA-ribosome complex. Figure adapted from [17]. 
 
1.1.3.3 DNA Replication Inhibitors 
 
Inhibition of DNA replication and transcription is an important target for 
antibacterial reagents. Quinolones, coumermycins and novobiocin are some of the DNA 
replication inhibitors. Quinolones are a class of synthetic antibiotics that interfere with 
DNA synthesis by inhibiting topoisomerase, an important enzyme involved in DNA 
segregation. Nalidixic acid is a member of the the first generation quinolones. 
Fluoroquinolones are the second-generation quinolones that include levofloxacin, 
norfloxacin, and ciprofloxacin. They are used against both Gram-negative and Gram-
positive bacteria. These antibiotics selectively block DNA gyrase by binding to the A 
subunit of the enzyme and they induce formation of relaxation complex analogue [11, 12]. 
The coumermycins and novobiocin also inhibit DNA gyrase, however, they bind to the 
ATP
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key enzymes involved in pyridime thymidylate for DNA biosynthesis [13]. Hence, folic 
acid biosynthesis pathway is an important antimicrobial target of the existing drugs and for 
pharmacological studies aiming to develop novel antibiotics. 
Sulfamethoxazole and trimethoprim are two drugs targeting folic acid synthesis. 
Sulfa drugs are competitive inhibitors and alternative substrates for DHPS and they block 
the enzyme dihydropteroate synthase (DHPS) in the pathway to folate. Trimethoprim 
inhibits dihydrofolate reductase (DHFR) in the last step of biosynthesis pathway[1, 13]. 
Figure 1.9 shows the folic acid pathway and the enzymes inhibited by antibiotics. 
 
 
 
Figure 1.9 The bacterial folic acid biosynthetic pathway, adapted from [1]. 
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1.2 Antibiotic Resistance 
 
Antibiotic resistance is the ability of microorganism to tolerate the inhibitory effects 
of antibiotic drugs. Bacteria can develop resistance against drugs by spontaneous mutations 
and horizontal gene transfer. The evolution and spread of antibiotic resistance has become a 
major threat to public health since a significant portion of the hospital acquired bacteria are 
resistant to multiple drugs. Uncontrolled antibiotic use and increased mobility of humans 
and animals in the modern world are two major factors responsible for the increased 
resistance[3]. Antibiotics act as selective agents and impose a growth advantage to 
bacterials strains that carry resistance conferring mutations or genes[14]. In hospitals, there 
is intensive and constant exposure of bacteria to antibiotics. Thus, antibiotic-resistant 
bacteria are more abundant in hospitals compared to community and nature [14].  
  
1.2.1 Mechanisms for Resistance 
 
Resistance can be described in two ways: intrinsic and acquired resistance. Intrinsic 
resistance is the innate ability of a bacterial species to resist toxicity of antimicrobial agents 
through its inherent genetic toolbox, which allow tolerance of a particular drug or 
antimicrobial class.  This natural insensitivity can be due to reduced affinity of the drug to 
target enzyme or molecule, innate production of enzymes that inactivate the drug, low 
permeability of drugs because of the pore sizes of membrane proteins, and reduced 
effective drug concentration as a result of overexpressed efflux pumps[15]. For instance, 
gram negative bacteria are naturally resistant to vancomycin, glycopeptides, due to limited 
uptake of these large-sized drugs[1]. Acquired resistance occurs when a naturally 
susceptible microorganism gets the ability to tolerate the toxicity of a particular 
antibiotic. Spontaneous mutations and the horizontal transfer of resistance conferring genes 
(mainly, transposable genetic elements) are two commons ways to acquire resistance[16]. 
Resistance genes have the ability of moving into other bacteria by different genetic 
mechanisms; such as, plasmids, bacteriophages and transposons[14]. For instance, 
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acquisition of resistance gene in Staphylococcus aureus causes methicillin resistance and 
nucleotide substitutions on the RNA polymerase genes give rise to rifampicin resistance in 
Mycobacterium tuberculosis[16]. 
There are three major mechanisms of antibiotic resistance; namely, enzymatic 
destruction or modification of the antibiotic by resistant bacteria, mutations or 
overexpression of efflux pumps, and replacement or modification of the antibiotic 
target(Figure 1.10) [17]. 
 
 
Figure 1.10 Mechanisms for Resistance. Antibiotic altering and degradingenzymes, 
alteration of drug target, resistance plasmids and upregulation of efflux pumps are major 
resistance mechanisms. “A” stands for antibiotic. 
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1.2.1.1 Enzymatic Destruction or Modification of Antibiotic 
 
 There are natural enzymes that can modify, cleave or inactivate some of the 
antibiotics. The most important example is the widespread occurrence of beta-lactamases in 
nature and clinic[18]. β- lactamase enzymes destroy the beta-lactam ring of penicillin and 
cephalosporin classes of antibiotics and render them useless [1, 18] . Today, more than 190 
β-lactamase genes have been identifiedand categorized into different classes: A, B, C and D 
[19]. Enzymatic mechanisms to inactivate the antibiotics are shown in Table 1.1. For 
example, while beta lactamases destroy drugs by hydrolysis, aminoglycosides and 
chloramphenicol are inactivated by adding acyl group [20]. 
Some strategies were developed to overcome resistance of beta-lactam antibiotics. 
One of these strategies is production of semisynthetic beta lactams that are harder 
substrates for lactamase degradation [1]. Thienamycin, carbapenem group antibiotics, are 
such examples that are hydrolysed by lactamases in a relatively slower rate. Another 
approach is finding inhibitors or inactivators of lactamases and using these molecules with 
β-lactam antibiotics. Clavunic acid, sulbactam, and tazobactam are commonly used 
inactivators of beta-lactamases[20]. Interestingly, some of these inhibitors are originally 
derived from β-lactam producing microorganisms. The combination of amoxicillin and 
clavulanate, known as Augmentin brand, has been one of the most widely used form of 
penicilin[1]. 
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Strategy Type Antibiotics Affected 
Hydrolysis  Beta-lactams 
Macrolides 
Group Transfer Acyl Aminoglycoside 
Chloramphenicol 
 Phosphoryl Aminoglycoside 
Macrolide 
Rifamycin 
 Thiol Fosfomycin 
 Nucleotidyl Aminoglycoside 
Lincosamide 
 Glycosyl Macrolide 
Rifamycin 
Other Redox Tetracycline 
Rifamycin 
 Lyase Streptogramin (typeB) 
   
 
Table 1.1 Different enzymatic strategies for inactivation of antibiotics[20]
 
1.2.1.2 Efflux Pumps 
The second important mechanism for drug resistance is exclusion of antibiotics 
from the cytoplasm via overexpression of efflux pumps or more active mutant efflux 
pumps[17]. The reduced effective antibiotic concentration inside the cells often have almost 
no inhibitory effect on bacterial growth and imposes a significant selective advantage to 
resistant strains[21].  Some efflux pumps are specific to certain antibiotics or antibiotic 
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classes such as macrolides, lincosamides, streptogramins and tetracyclines, whereas several 
other pumps, also known as multiple drug resistance pumps, can pump out several 
structurally diverse drugs [21].  Such multidrug resistance proteins (pumps) are frequently 
seen in clinical isolates that are resistance to almost all available antibiotics. There are five 
families of efflux-pump proteins associated with multi drug resistance (MDR): the ATP 
binding cassette (ABC) superfamily, the major facilitator superfamily (MFS), the multidrug 
and toxic-compound extrusion (MATE) family, the small multidrug resistance (SMR) 
family, and finally the resistance nodulation division (RND) family[22]. MDR efflux 
pumps are categorized according to the number of components these pumps carry (single or 
multiple), the number of transmembrane-spanning structures, the energy source that the 
pumpsutilize, and the types of substrate specific to the pumps. This kind of resistance 
mechanism can occur through spontaneous mutations in genes coding for efflux pumps or 
the transcription factors regulating the expression of these genes[22].   
Figure 1.11 shows the five families of multidrug-resistance efflux pumps and 
common examples of the individual proteins that form each class of efflux pump in gram-
negative and gram-positive bacteria. AcrAB are an example of RND type MDR efflux 
pumps and detailed structure and schematic model of AcrAB-TolC system is indicated in 
Figure 1.12. A single organism can express MDR efflux pumps of more than one family or 
more than one type of efflux pumps of the same family. For example, Escherichia coli have 
20 MFS, 3 SMR and 7 RND members, for a total of 30 efflux pumps[1].  
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Figure 1.11 Diagrammatic representation of the structure and membrane location of efflux 
pumps from five families of multidrug-resistance efflux pumps: the ATP-binding cassette 
(ABC) superfamily, the major facilitator superfamily (MFS), the multidrug and toxic-
compound extrusion (MATE) family, the small multidrug resistance (SMR) family and the 
resistance nodulation division (RND) family, adapted from [22] 
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1.2.1.3 Modification of the Antibiotic Target 
 
Some resistant bacteria get rid of antibiotics when critical target sites are mutated 
and drug affinity is compromised. Most of the antibiotic targets have very important 
enzymatic functions so organisms cannot completely reduce antibiotics by getting rid of 
target enzymes via loss of genes. However, it is possible for them to reduce drug 
susceptibility via mutational changes in the target. In some cases, it was reported that the 
modification of target structures requires other changes in the cell genome to compensate 
for the reduced or altered activity of the target enzymes[24].  
One of the most important examples of target modifications in the context of drug 
resistance is the altered transpeptidase, MecA in Staphylococcus aureus that confers 
resistance against methicillin (methicillin-resistant S. aureus, or MRSA) and many other β-
lactam antibiotics [1]. Alterations in penicillin binding proteins (PBP) are other 
mechanisms observed in many bacteria and make them resistant to beta-lactam antibiotics; 
such as, S. pneumonia, Streptococcus pyogenes, Neisseria meningitides, enterococc,and 
Helicobacter pylori. The altered PBPs are usually generated by recombination events 
(transformation) between the PBP genes of S. pneumoniae and related PBP genes from its 
streptococcal relatives[24]. 
Mutations in RNA polymerase and DNA gyrases result in resistance to the 
rifamycins and quinolones, respectively. Fluoroquinolone-resistant bacteria generally have 
mutations in GyrA or GyrB subunits of DNA gyrase. Mutations in this region cause 
resistance due to reduced decreased drug affinity[25]. Mutations in the β-subunit of RNA-
polymerase (rpoB) increase rifampicin resistance in Mycobacterium tuberculosis [24]. 
Resistance to MLS group antibiotics is observed in both gram-positive and gram-
negative bacteria. Post-transcriptional modification of the 23S rRNA component of the 50S 
ribosomal subunit (methylation or dimethylation of key adenine bases in the peptidyl 
transferase functional domain) is responsible for the elevated resistance [1, 24]. Mutations 
on the 16S rRNA subunit of the ribosome cause resistance for aminoglycoside antibiotics. 
For example, amino acid substitutions are frequently observed in Mycobacterium abscessus 
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clinical isolates, and are responsible for phenotypes that are highly resistant against 
amikacin, gentamicin, kanamycin, neomycin, and tobramycin. Additionaly, trimethoprim 
resistance in bacteria occurs through mutation in the DHFR gene producing single amino 
acid substitution in the dihydrofolate reductase target enzyme [1, 24]. Such target mutations 
are found in almost all antibiotics and hence impose serious problems in microbial diseases. 
Chemical improvement of existing antibiotics is promising approach to tackle this problem. 
 
1.2.2 Multidrug Resistance 
 
Multidrug resistance (MDR) is a condition in bacteria that makes them resistant to 
different classes of antibiotics simultaneously. Use of vast amounts of antibiotics in 
hospitals, in husbandry, and agriculture has a significant contribution to this problem since 
many bacterial populations are exposed to different antibiotics several times within short 
time periods. For example, clinically isolated methicillin resistant Staphylococcus aureus 
(MRSA) strains are often found to be resistant not only to methicillin but also to many of 
the aminoglycosides, macrolides, tetracycline, chloramphenicol, and lincosamides[26]. 
Unfortunately, MRSA is not the only example for multidrug resistant bacteria;vancomycin-
resistant enterococci (VRE), MDR–tuberculosis, Acinetobacter, and Salmonella typhiare 
other clinically important pathogens. 
Multidrug resistance is often acquired by upregulation of genes that code for efflux 
pumps and drug target enzymes, and accumulation of various resistance conferring 
transposable genes[26]. Figure 1.13 shows accumulation of multiple genes, each coding for 
resistance to a single drug, on resistance (R) plasmids.  R plasmids are well maintained 
genetic elements that are transferred efficiently from cell to cell. Assembly of resistance 
plasmids are done via accumulation of multiple resistance genes by mechanisms provided 
by transposons, and integrons[26]. 
The active pumping out of drugs by multidrug efﬂux pumps is the one of the key 
mechanisms regarding multidrug resistance. Resistance-nodulation-division (RND) pump 
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superfamily; such as, AcrB of E. coli and MexB of P. Aeruginosa, are two well known 
examples MDR related efflux pumps [26]. In addition to RND family, several multidrug 
efﬂux transporters belonging to the Multidrug and Toxin Extrusion (MATE) and ABC 
superfamily play important roles in MDR. Most gram-negative pathogens can contain 
several endogeneous genes coding for such pumps, and their expression may become 
upregulated via mutations on the regulatory regions, increasing resistance to many 
antimicrobial agents simultaneously with one or two small genetic changes. 
 
 
Figure 1.13. Map of an Resistance plasmid R100. Tetracycline resistance gene tetA is in the 
transposon Tn10, chloramphenicol acetyltransferase (cat) as a part of Tn9, and sulfonamide 
resistance gene sul1 and an aminoglycoside adenyltransferase gene aadA1 as a part of the 
large transposon Tn21. This ﬁgure is based on the nucleotide sequence deposited by 
GenBank sequence NC 002134[26] 
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1.2.3 Evolution of Drug Resistance in Laboratory conditions 
 
 The rate of adaptation to high doses of antibiotics and genotypic paths to resistant 
phenotypes can be investigated by well designed laboratory evolution experiments. 
Traditional selection experiments, continuous culture devices, and state-of-the-art 
microfluidic devices are currently used for studying evolution of antibiotic resistance in 
laboratory settings that mimic natural settings[16]. Conventionally these experiments are 
carried out by exposing bacteria to fixed drug doses until resistant mutants are observed. 
This is quite a touchy procedure since finding the appropriate  mutant selection window is 
not straightforward; drug concentrations should be high enough to inhibit growth of the 
parental drug sensitive strain but yet low enough in order to allow some resistant mutants 
survive [27]. This approach usually reveals only a few initial adaptive steps. Continuous 
culture devices facilitate multistep experimental evolution and reveal genetic pathways 
when combined with whole genome sequencing[28]. For example, a recently developed 
continuous culture device, the morbidostat, continuously adjusts antibiotic concentration 
according to the actual rate in which resistance evolves to maintain nearly constant growth 
inhibition of an evolving microbial population[28]. Microfluidic devices can also carry out 
multistep experimental evolution in spatial drug gradients[16]. 
 
1.3 Drug combinations and evolution of resistance 
 
Antimicrobial treatments increasingly rely on simultaneous use of multiple drugs 
because of rapid emergence and spread of antibiotic resistance in clinic and limited supply 
of new antibiotics. The idea simply comes from the expectation that the chance of 
developing two or three drugs simultaneously is slim. Thus, researchers have been trying to 
find drug pairs that would perform better when combined togetter. This approach is quite 
tedious in the sense that drug pairs often behave unexpectedly due to the interactions 
between them. Such interactions between drugs are classified as synergistic, antagonistic 
and additive according to whether the combined effect of the drugs is larger than, equal to 
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or smaller than the effect predicted by their individual activities[29, 30]. Figure 1.9 
represents drug interactions schematically. 
Clinicians have favored synergistic drug pairs for a long time since synergistic drug 
combinations generate increased efficacy at lower doses, and not surprisingly antagonistic 
pairs are generally avoided in clinical applications[27]. However, recent in vitro laboratory 
studies suggested that antagonistic drug pairs may have lower efficacy but have the 
potential to slow down the evolution of drug resistance, and synergistic drug combinations 
may be worse since resistance seem to evolve faster[29, 31]. An experimental study 
conducted by Hegreness et al (2008) showed that evolution in synergistic drug 
combinations is faster than evolution in antagonistic combinations and each drug 
separately[30]. Interestingly, this phenomenon was also predicted in an old study by Klein 
and Schorr (1952).  According to Klein and Schorr, the rate of development of resistance to 
the antibiotics should be known for combined therapy and there is a correlation between the 
development of resistance and synergism between drugs that are combined. It was shown 
that in the cases when bacteria developed resistance after growing in each of two 
antibiotics, these two drugs were frequently found to be synergistic and never antagonistic. 
When the bacteria did not develop resistance in a rapid way, synergism rarely was the case 
and antagonism was observed frequently. This was indeed in good agreement with some 
clinical applications as well. For example, the combination of streptomycin and p-
aminosalicylic acid is used in the treatment of tuberculosis although they are antagonistic 
drug pairs. In this case, the infectious pathogen can develop resistance to one of the 
chemotherapeutic agents, but since these drugs have separate modes of action,the other 
drug can still inhibit the resistant cells until the pathogen becomes resistant to both of the 
drugs simultaneously [32]. 
 
 
 
 
 1.4 Cross Resistance
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The first and simplest reason of cross resistance is close chemical similarity of 
antimicrobial agents, resulting in parallel biological effects. A second explanation can be 
that chemically different agents may interfere with the same metabolic pathway. For 
example, one agent may block an enzyme system, whereas another drug may form a 
complex with intermediary products in the same chain of biochemical events[34]. Other 
mechanisms for cross resistance can be activation of multi drug efflux pumps or decrease 
permeability of cell membranes.A study done by Syzbalski et al. (1952) also demonstrated 
that resistant strains of circulin and polymyxin B, which are microbiologically similar 
drugs, show 2 to 8 times higher resistance to three related actinomyces antibiotics and also 
to streptomycin. Their mechanism of action is alteration of structure of cell membrane that 
results in more permeability. They showed considerable degree of reciprocal cross 
resistance for each other[34]. 
 
Another recent research conducted by Dragosits et al. (2012) shows how cross-
stress tolerance emerges during evolutionary adaptation. They used four different stress 
factors: osmolarity, acidity, oxidation, and n-butanol. As a result of the study, evolutionary 
cross-stress tolerancewas observed. For instance, n-butanol-adapted strains had very high 
fitness in hyper-osmatic conditions which was very close to the fitness of osmatic-adapted 
strains. They found stress factor specific mutations and also mutations in acrA gene that is 
involved in the acr multidrug efflux system. According to this study, if specific stresses had 
similar effects at a cellular level, high degree of cross-stress protection could be 
expected[35]. 
Systematic studies on evolution of cross resistance in the context of antibiotics are 
crucial both from basic science and clinical perspectives. These studies have the potential 
for providing genetic and biochemical information relevant to the development of 
resistance[34].  
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2.AIM OF THE STUDY 
 
 
Understanding genetic changes that elevate antibiotic resistance is of great 
importance to develop alternative antibiotic therapies that aim to slow down evolution of 
resistance. In this study, our goal was to design and test novel strategies for minimizing the 
rate of evolution of drug resistance. In the first part of this project, we carried out long term 
evolution experiments to reveal genetic evolutionary pathways that lead to antibiotic 
resistant phenotypes. In the second part, we constructed a large and unique data set that will 
allow us map genetic changes responsible for elevated resistance by carrying out high 
throughput phenotyping measurements and whole genome sequencing of drug resistant 
strains. Successful completion of this project will guide us find generalized rules for 
designing drug therapies and provide a clear correlation between genotype and phenotype. 
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3. MATERIALS & METHODS 
 
 
3.1 Materials 
 
3.1.1 Chemicals & Media Components 
 
Table 3.1 Chemicals used in the study 
 
 
Chemicals and Media Components Supplier Company 
Acetone Merck,Germany 
Agar-Agar Merck,Germany 
Antibiotics Sigma, Germany 
Chloroform Sigma,Germany 
DMSO Sigma,Germany 
Ethanol Merck ,Germany 
Glucose Sigma, Germany 
Hydrochloric Acid Merck, Germany  
Luria Broth Merck, Germany 
Magnesium Sulfate Sigma, Germany 
M9 Minimal Salts, 5X Sigma, Germany 
Protein Hydrolysate Amicase Fluka,Germany 
Sodium Chloride Applichem, Germany 
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3.1.2 Antibiotic and Chemical Solutions 
 
1M MgSO4 (MW:246,48) 
12.324 gr MgSO4 was dissolved in 50 mL distilled water. 
1M CaCl2     (MW:147,02) 
1,47 gr CaCl2 was dissolved in 10 mL distilled water. 
 
Antibiotic solutions from Sigma were made from powder stocks as indicated in Table 3.1 
and solutions were kept in -20 0C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2 All antibiotics and stock concentrations used in this study 
Antibiotics Solvent Stock Solutions 
Chloramphenicol  Ethanol 20 mg/ml 
Tetracycline  Ethanol 10 mg/ml 
Nitrofurantoin  DMSO 20 mg/ml 
Sulfamethaxozole  Acetone 20 mg/ml 
Kanamycin  Water 20 mg/ml 
Doxycycline  Water 10 mg/ml 
Trimethoprim  DMSO 10 mg/ml 
Streptomycin  Water 50 mg/ml 
Ampicillin  Water 20 mg/ml 
Nalidixic acid  Chloroform 20 mg/ml 
Ciprofloxacin  0.05 M HCL 10 mg/ml 
Amikacin  Water 20 mg/ml 
Cefoxitin sodium  Water 10 mg/ml 
Piperacillin  Water 10 mg/ml 
Tobramycin  Water 10 mg/ml 
Spectinomycin  Water 50 mg/ml 
Lomefloxacin  Water 10 mg/ml 
Fusidic Acid  Water 20 mg/ml 
Erytromycin  DMSO 20 mg/ml 
Clindamycin  DMSO 10 mg/ml 
Spiramycin  Ethanol 20 mg/ml 
Sulfamonomethoxine   Acetone 10 mg/ml 
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3.1.3 Bacterial Growth Media 
 
M9 minimal medium supplemented with 0, 4% glucose and 0, 2% amicase was 
used for liquid culture of bacteria. 11.28 gr M9 minimal salts was dissolved in 1 L of 
distilled water and autoclaved at 121oC for 15 min. 50 gr glucose was dissolved in 500 mL 
distilled water and autoclaved at 121oC for 15 min. Glucose solution was prepared as 25 X 
and diluted in media as last concentration will be 1X. Amicase was prepared as 10 X and 
filter sterilized with Corning, CA memrane 0,22 micron bottle top filters.  2 mL of sterile 1 
M magnesium sulfate and 0.1 mL of 1 M sterile calcium chloride was added to 1L of M9 
minimal medium.  
Luria Broth from Merck was used for liquid culture of bacteria. 25 g of LB Broth 
was dissolved in 1 L of distilled water and autoclaved at 121oC for 15 min. LB agar from 
Merck was used for preparation of solid medium for the growth of bacteria. 12-15 g of LB 
agar was dissolved in 1L distilled water and autoclaved at 121oC for 15 min. Medium was 
poured onto sterile Petri dishes (20 mL/plate). Sterile solid agar plateswere kept at 4oC. 
 
3.1.4 Bacterial Strains  
 
All experiments were performed with the drug-sensitive, wild type MG1655 E.coli strain. 
 
3.1.5 Equipment 
 
All equipment used in this study are shown in Table 3.3. 
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Equipment     Company 
Autoclave                                            Priorclave, UK 
 Balance    Sartorius, BP610, Germany 
                                                            Schimadzu, TW423LV, Japan 
Deep Freeze     -80 0C, New Brunswick Sci.,U410,USA 
     -20 0C, Regal,Turkey 
Distilled Water   Millipore, Elix-S, France 
Incubator      Memmert, Modell 300, Germany 
Laminar Flow                                      Heraeus, Germany 
Microliter Pipettes    Gilson, Pipetman, France 
Microscope     Olympus CK40,Japan 
                                                            Olympus CH20,Japan 
                                                             Olympus IX70,Japan 
Plate Reader    TECAN Infinite F200 pro 
                                                            TECAN infinite M200pro 
Pinner                                                  V&P Scientific,USA 
Plate Shaker Incubator                        Heidolph,Germany 
Refrigerator     Regal,Turkey 
Shaker Incubator      New Brunswick Sci., Innova 44, USA 
                                                            New Brunswick Sci., E24,USA 
Spectrophotometer    Amersham Biosciences, UK 
Vortex                                                 VWR,USA 
Whole-genome sequencing                Illumina Gene Analyzer IIx, USA 
 
Table 3.3 Equipment used in the study 
 
3.1.6 Software 
MatLab and Samtools Software kit were used for data analysis. 
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3.2 Methods 
 
3.2.1 Bacterial Cell Culture 
 
 E.coli (MG1655) strain was grown 24 hours at 30 0C shaking at 200 rpm in 
sterile M9 minimal medium supplemented with 0.4% glucose and 0.2% amicase. Bacterial 
strains either streaked or spreaded were grown on LB agar petri dishes overnight. Growth 
temperature on LB agar medium was 37oC. Single colonies were picked from LB agar petri 
dishes. Experiments were started from single colony of E.coli. For the glycerol stock 
preparation of bacterial cells, glycerol was added to the overnight grown bacterial cultures 
to a final concentration of 15%. Cells were frozen and stored in multiple aliquots at -80oC. 
 
3.2.2 Measurement of Growth Rate 
 
 Growth rate was measured as prepared in 96-well plates, with 150 µl per well by 
TECAN. Matlab program was used to analyze the growth rate of strains. 
 
3.2.3 Determination of Minimum Inhibitory Concentrations (MIC)  
 
 MIC line of antibiotics was measured by a standard overnight growth assay in 
liquid media, inoculating wild type E.coli in each of 96 wells. 150 µl minimal media was 
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added per well and antibiotic solutions was diluted serially with two fold intervals in each 
column. For each drug, typically 11 different concentrations were tested. 
 The MIC line was defined as the line separating regions of growth and no 
growth. Practically, the lowest drug concentration at which background-subtracted OD was 
less than 0.04 after 24 h was defined as MIC. 
 
3.2.4 Evolution Experiments 
 
 MIC values of each drug were identified by serial dilution method as described 
above. Antibiotic solutions were prepared in different stock concentrations from power 
stocks and stored in -20 0C.  
 On the first day of the experiment, 4 replicates of six different concentrations of 
each drug with twofold intervals were prepared in 3 ml M9 minimal medium. Drug 
concentrations were prepared according the MIC values of antibiotics. Starting OD of the 
each culture was 0.00005; indicating that approximately 25x103 bacteria were inoculated. 
On the second day, cultures were separated as duplicates for strong and weak selections and 
these parallel cultures were not mixed after the first starting culture. Growing cultures were 
identified by spectrophotometer and by visual examination. 100 µl of grown cultures were 
added to newly prepared 3 ml cultures; that is, 30 fold dilutions were made in each day.  
For strong selection, always last growing culture was continued to the next day. For weak 
selection, bacteria were chosen from two behind the last growing culture. By this way, 
different selection powers were applied on bacteria cultures. Drug concentrations were 
adjusted according to growth conditions of cultures in every day. If there was no growth in 
one day, same drug concentrations were applied in next day.  If evolution was observed, 
drug concentrations were increased and glycerol stocks were prepared and stored. 
Evolution experiments were continued for 21 days. Figure 3.1 shows the schematic 
overview of evolution experiments. 
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Figure 3.1 Schematic representations of evolution experiments. Yellow color shows weak 
selection and red color shows strong selection.  
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3.2.5 Phenotypic Characterization 
 
 3.2.5.1 Representative Colony Selection 
 
 After 21 days of evolution experiments, 88 evolved strains (4 strains for each 
antibiotic) were obtained. . Mixed cultures were streaked on LB agar medium without drug 
and grown at 37 0C. Ten representative colonies were picked randomly from each mixed 
cultures of evolved strains and cultured in liquid medium. Their MIC values were identified 
by serial dilution on 96-well plates. If MIC of a colony is same with MIC of mixed 
cultures, it was called as representative colony. 
 
3.2.5.2 Growth Data 
 
 Master plates were prepared from representative colonies of evolved cultures. 
The cells in master plates were transferred into experimental plate, including 150 µl 
minimal media per well, using a 96-pinner. Cells in 96 well plates were grown in the 
TECAN-M200 for 24 hours at 300C, with taking data points in every 10 minutes. Growth 
curves and rates were determined for 88 evolved cultures.  
 
3.2.5.3 Cross Resistance 
 
 For each antibiotic, several experimental plates were prepared in the range of 
MIC/4 to 2 fold of highest MIC of evolved strains with square root 10 (approximately 3, 
16) intervals. The cells in master plates were transferred into experimental plates using 
pinner. Cultures were grown at 300C for 24 hours with rapid shaking. Experimental design 
was explained in Figure 3.2. Growth was measured in TECAN at 600nm and cross 
resistance data were analyzed in Matlab. 
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Figure 3.2 Experimental design of cross resistance. The plate on the left part has highest 
drug concentration. Drug concentrations are reduced 3.16 folds for each plate and last one 
has no drug. Bacteria are inoculated from master plate with pinner. 
 
 
3.2.6 Genotypic Characterization 
 
3.2.6.1 Next Generation Sequencing: Illumina  
 
 The automated Sanger method is considered as a ‘first-generation’ technology, 
and newer methods are referred to as next-generation sequencing (NGS). Currently, 
Illumina Genome Analyzer dominates the NGS market. It uses the clonally amplified 
template method coupled with the four-colour CRT method[36]. 
 
3.2.6.2 Whole Genome Sequencing 
 
 Representative colonies of each culture were sent to Genewiz NGS-Laboratory, 
USA in agar stabs for whole genome sequencing. DNA purifications of cultures were done 
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by Genewiz Company. Illumina genome analyzer IIx (101-bp single end reads, minimum 
coverage 100x per strain) was used for whole genome sequencing.  
 
3.2.6.3 Mutation and Amplification Analysis 
 
 Reads of genome sequencing were aligned onto the MG1655 reference 
chromosome (NC_000913.2) using the Illumina pipeline. SNPs were identified with 
SAMtools. 
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4. RESULTS 
 
 
In this study, 88 E. coli populations were evolved in increasing concentrations of 22 
clinically relevant antibiotic compounds for ~100 generations. By using Illumina whole 
genome sequencing100 drug resistant strains and carrying out phenotyping measurements, 
we constructed a large data set that allows us to map genetic changes responsible for 
elevated resistance. 
 
4.1 Bacterial Evolution Results 
 
4.1.1 Evolution Strategy 
 
In the first part of this study, we conducted microbial evolution experiments to 
generate antibiotic resistant strains which will be used to understand the genetic changes 
that elevate antibiotic resistance and compare level of cross resistance between antibiotics. 
A total of 22 different antibiotics from different classes were used in this study. Table 4.1 
shows the antibiotics and their mechanisms of actions. We tried to choose at least 3 
antibiotics from different classes except nitrofurantoin which carries multiple modes of 
action. As summarizedin methods section, selection procedure was carried at two different 
selection strengths in order to investigate the differences in the evolutionary process and 
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role of selection strength in the target specificity of drugs. For each antibiotic compound we 
used four replicates: two replicates for strong and two replicates for weak selection.Drug 
concentrations that applied relatively similar selection were updated and accordingly 
adjusted almost each day and evolved bacteria were transferred to the newly prepared 
cultures on a daily basis. Figure 4.1 shows our experimental design for microbial evolution.  
 
Table 4.1 All antibiotics used in this study and their mechanisms of actions 
Antibiotics  Main mechanisms of action 
Chloramphenicol Protein Synthesis, 50S 
Clindamycin Protein Synthesis, 50S 
Erythromycin Protein Synthesis, 50S 
Spiramycin Protein Synthesis, 50S 
Fusidic Acid Protein Synthesis, 50S 
Tobramycin Aminoglycoside, protein synthesis,30S 
Amikacin Aminoglycoside, protein synthesis,30S 
Kanamycin Aminoglycoside, protein synthesis,30S 
Streptomycin Aminoglycoside, protein synthesis,30S 
Tetracycline Protein synthesis,30S 
Doxycycline Hyclate Protein synthesis,30S 
Spectinomycin Protein synthesis,30S 
Ampicillin  Cell wall 
Piperacillin Cell wall 
Cefoxitin Cell wall 
Lomefloxacin DNA gyrase 
Ciprofloxacin DNA gyrase 
Nalidixic Acid DNA gyrase 
Trimethoprim Folic acid biosynthesis 
Sulfamonomethoxine Folic acid biosynthesis 
Sulfamethoxazole Folic acid biosynthesis 
Nitrofurantoin Multiple mechanisms 
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Figure 4.1 Experimental design. A) Red shows the strong selection, yellow shows the weak 
selection. For strong selection, always last growing culture was chosen and for weak 
selection two behind of the last growing culture was taken. Experiment continues for 21 
days. B) With the increasing of time and stress factors, resistance levels of bacteria also 
increase. 
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4.1.2 Bacterial Evolution Results 
 
88 isogenic wild type drug sensitive E. coli populations evolved in increasing 
concentrations of 22 clinically relevant antibiotic compounds for ~100 generations. Figure 
4.2 exhibits all adaptation trajectories. Red lines represent the phenotypic changes of 
populations that were evolved under strong selection whereas black lines represent the 
phenotypic changes of populations that were evolved weak selection. Resistance levels of 
many populations increased several orders of magnitude after 21 days. These MIC values 
were further verified with measurements done in 96 well plates and a TECAN microplate 
reader. These populations were evolved in the presence of sulfamethoxazole, cefoxitin, 
tobramycin, streptomycin, and spectinomycin became super resistant. However, in some 
cases, resistance levels increased only ~ 10 folds. For example, MIC values for doxycyline 
and tetracycline resistant populations increased 8 and 16 folds, respectively.  
 
Using the adaptation traces, we were able to compare levels of evolved resistance 
and rate of adaptation for all of the evolving populations. Our data suggest that in many 
cases, populations under strong selection reached to higher levels of resistance. Differences 
between selection strengths can be easily seen with the populations evolving in the 
presence of tobramycin, spectinomycin, and nitrofurontoin. Strongly selected resistant 
strains of these antibiotics have very high resistance levelscompared to the weakly selected 
ones. For instance, nitrofurontain resistance of strongly selected populations is 
approximately 50 times higher than the weakly selected populations. In fact, weakly 
selected populations only developed two fold increases in their MIC. On the other hand, 
selection strength did not affect the evolved resistance levels in some cases; such as: 
doxycycline, tetracycline, clindamycin, and nalidixic acid. Resistance to these drugs 
reached to same levels in both weak and strong selection strategies. Figure 4.3 shows the 
scatter plot of MIC values for strong versus weak selection for all 22 antibiotics we used. 
As anticipated, MIC values for strongly selected populations were higher in most cases. 
Finally, for some cases, we observed that the resistance levels of replicates, especially in 
strong selection mode, were significantly different than eachother. For example, for 
piperacillin, one of the strongly selected populations had ten fold higher resistance than the 
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other strongly selected population.Variation levels between replicates are represented by 
the error bars (standard deviation) in the scatterplot in figure 4.3.In summary, over time, the 
resistance level increased dramatically, with similar changes in parallel evolving 
populations.  
 
 
Figure 4.2 Microbial Evolution to 22 drugs.E.coli populations rapidly evolved high 
antibiotic resistance. Sample measurements of MIC versus time. 
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Figure 4.3 Comparison of MIC-Strong versus MIC-weak values. Error bars show variation 
levels between replicates. Red line indicates equality of MIC-strong and weak. 
 
4.1.3 Representative Colony Selection 
 
 We plated population samples from the final day of the experiment and randomly 
selected ten colonies. We carefully quantified MIC values for each isolated colony; MIC 
values’ distributions are shown in Figure 4.4. Although some minor fluctuations in MIC 
values were observed, majority of these colonies had similar phenotypes with the 
populations they were isolated from. One colony from each population that had the highest 
MIC value among all of the colonies was isolated as the representative colony for further 
genotypic and phenotypic investigation.  In Figure 4.4, phenotypic distributions of the 
colonies for one example from each drug classare shown. The entire distribution data set 
can be found in appendix A. Representative colonies were sent for Illumina whole genome 
sequencing, and a master plate carrying all of the representative colonies was prepared to 
be used in phenotypic measurements. 
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Figure 4.4 MIC values of colonies for each evolved strains of chloramphenicol, 
tetracycline, sulfamethoxazole, streptomycin and lomefloxacin antibiotics. 10 colonies 
were selected from each evolved culture of drugs and shown in x-axis. MIC values of 
colonies are indicated on the y-axis. Blue and red colors show strongly selected first and 
second strains, respectively. Green and purple colors are for weakly selected strains.Graphs 
are shown in logarithmic scale. 
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4.2 Cross Resistance 
 
Resistance levels of all representative colonies against all 22 drugs were carefully 
quantified using a high-throughput assay as described in methods. Figure 4.5 shows sample 
phenotypic measurements where green line indicates the growth of wild-type, red line 
indicates the elevated resistance, and blue line indicates increased sensitivity. As expected, 
colonies had high resistance to the drugs they were evolved against. We call this type of 
resistance as “direct resistance”. We observed cross resistance mostly within the strains that 
were evolved in drugs belonging to the same class but there were several exceptions 
showing increased cross resistance against antibiotics that belong to different classes as 
well. To our surprise, we also found many cases where some strains developed increased 
sensitivity to several other drugs. After repeating these measurements for all of the strains, 
we ended up having 1958 phenotypic measurements and combined all the data in a matrix 
shown in Figure 4.6 for better representation. 
Figure 4.6 shows the full matrix of the phenotypying data. We placed evolved 
strains on the x- axis and the antibiotics they were phenotyped on the y-axis. Color map for 
increased resistance arranged between light pink and red. All of the resistance values were 
normalized with the highest direct resistance value; hence, the diagonal line from bottom 
left to upper right is mostly surrounded with dark red pixels. Similarly, phenotypes with 
increased susceptibility are represented with colors between light blue and dark blue.  
White colored pixels represent phenotypes that do not have any difference from the wild 
type parental strain in terms of MIC. 
In order to better understand the data set, we divided the full matrix into strong and 
weak data as shown in Figure 4.7A and 4.7B. As expected, the levels of resistance in strong 
data is higher and this is reflected with the relatively darker colors compared to the weak 
matrix.  
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Figure 4.5 Identification of cross resistance of chloramphenicol and kanamycin strains to 
tobramycin. Green line shows the wild type, red line shows the increased resistance and 
blue line indicates increased sensitivity. 
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Figure 4.7 B) Cross resistance matrix of weak selection strain. Blue indicates sensitivity, 
red shows resistance and white means same with wild type. In the x axis, weakly evolved 
strains were place and in the y-axis, antibiotics were placed. All strains and antibiotics were 
arranged as same classes of drugs are close to each other. 
 
Figure 4.7B shows the weak phenotyping data set. Colors are lighter than strong 
selection but general pattern is similar to strong selection. Reciprocal behavior was 
observed within the same drug groups not across different drug classes with a few 
exceptions. For instance, spectinomycin and clindamycin resistant strains reciprocally 
evolved cross resistance. 
In order to test the reproducilibity of the phenotyping measurements, we repeated 
all of the measurements independently and compared them with the original measurments 
as shown in Figure 4.8 and found that data was reproducible for more than 95%. 
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Figure 4.8 Quality control of cross resistance data set: More than 95% reproducibility 
 
 
To better understand the mechanism of resistance, we made some generalization for 
drug classes and tried to form a simple view of the matrix, shown in Figure 4.9. Reciprocal 
evolution was observed in most of the same drug classes except protein synthesis-30S 
inhibitors. All drugs of DNA gyrase inhibitors and cell wall inhibitors had reciprocal 
evolution in their groups. We did not observe general pattern of reciprocal evolution across 
the groups. According to our cross resistance data, aminoglycoside resistant strains became 
more susceptible to nitrofurantoin, protein synthesis-50S, DNA gyrase and folic acid 
metabolism inhibitors. Resistant strains of protein synthesis-30S inhibitors did not show 
cross resistance behavior mostly. Only doxycycline resistant strains get resistant toward 
tetracycline but interestingly tetracycline resistant strains did not get any resistance to 
doxycycline. Additionally, Figure 4.9 shows that evolved strains of DNA gyrase inhibitors 
become resistant to cell wall inhibitors and evolved strains of nitrofurontain, a multiple 
mechanism drug, get resistant to folic acid biosynthesis inhibitors. 
  
Figure 4.9 Cross resistance interactions by drug groups:
synthesis
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4.3.1 WGS - Mutation (SNP) Results 
 
 Whole genome sequencing of 88 strains identified mutations and revealed that 
selection power affects the mutation types. By analyzing mutations, we tried to understand 
how selection power affects the target specificity. There were many drug-specific 
mutations, and some shared mutations.In some cases strong selection strains of same 
antibiotic had different mutations. Figure 4.10 shows the mutated genes for all drug 
resistant strains except from cefoxitin strong selection strains as a network. We could not 
show each mutated genes of cefoxitin strain since strong selection strains of cefoxitin drug 
had ~ 200 mutations. We saw that some genes are shared in different classes of antibiotics 
for mutations; such as, fusA, fis, marR, rph, trkH, ompR, ompF, acrR, mprA and gyrA. 
Table 4.2 shows the functions of these shared genes, mutation spots and number of 
mutations on the gene. All mutation positions and functions of mutated genes are given in 
appendix B as a table. 
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Table 4.2 Shared mutated genes across the antibiotic classes 
 
 
Mutated  
Gene 
Function of gene Mutation points #of 
mutations 
fusA 
 
Protein chain elongation factor, 
Translation 
G117C(2),V126G, 
R371L,L438Q(3),I545T, F605L, 
I654N, P659L,A678V 
 
     12 
fis 
 
DNA - binding transcriptional dual 
regulator 
R5L, 69INDEL71, 
39INDEL99 
 
     3 
marR 
 
DNA-binding transcriptional 
repressor of multiple antibiotic 
resistance 
R27P, L46H,  
84INDEL103 
 
     3 
rph defective ribonuclease PH 207INDEL229      5 
ompF outer membrane porin,1a 10INDEL27, 158INDEL163, 
191INDEL239, 213INDEL240, 
Q361X 
 
5 
ompR 
 
DNA-binding response regulator in 
two-component regulatory system 
with EnvZ 
E3X, 8IND44, R15C, E96D , 
176IND183 
 
     5 
acrR 
 
DNA-binding transcriptional 
repressor 
Q7X (2), S31T,  
84IND103, A191D 
     5 
gyrA 
 
DNA gyrase , subunit A S83L (8 ), D87N, D87T 
S464T, P738S(2) 
 
    13 
mprA DNA binding transcriptional 
repressor of microcin B17 synthesis 
and multidrug efflux  
 
120INDEL134, 
125INDEL176, 
160INDEL176 (2) 
 
 
     4 
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Figure 4.10 Mutation networks of antibiotic classes. Same drug groups are shown in same 
color and drugs are indicated as hexagon. Names of mutated genes are shown in circles. 
There are many drug specific mutated genes and some shared mutated genes. 
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We classified mutated genes according to their related functions; such as: 
translation, transcription, membrane proteins, DNA replication, folic acid metabolism and 
unknown functions. Antibiotics were also grouped according to their mode of actions, 
shown in Figure 4.11A. Evolved strains of all antibiotic classes have mutations on 
membrane proteins related genes except 50S inhibitors. Evolved strains of 50 S inhibitors 
have mutations on translation and transcription related genes. Additionally, all antibiotic 
groups have transcription related mutations; especially, they have acrR and marR 
mutations. 
AcrR, local repressor, plays a modulating role in the regulation of acrAB genes of 
Escherichia coli by global stress signals and acrAB genes encode a multidrug efflux pump 
in E.coli [41]. The MarR is the repressor of the multiple antibiotic resistance (marRAB) 
operon in E.coli. Inactivation of marR results in increased expression of marA, which acts 
at several target genes in the cell leading to reduced antibiotic accumulation[37]. 
Strains of DNA gyrase inhibitors have mutations on transcription, cell membrane 
and DNA replication related genes. Mutations of folic acid inhibitors are related with folic 
acid metabolism, transcription and membrane proteins. As expected, all of the protein 
synthesis inhibitors have mutations on translation related genes but other drug classes do 
not have mutations on translation genes. All antibiotic classes including nitrofurantoin have 
unknown mutations. 
Evolved strains of nitrofurantoin have mutations mainly on transcription related 
genes; such as: ompR, rpoA and mprA, and also mutations related with membrane proteins 
genes: motB.  Only nitrofurantoin has mutation on motB gene.  Product of this gene is 
MotB protein (motility protein B), an integral membrane protein, and required for rotation 
of the flagellar motor[38]. Nitrofurantoin is a multiple mechanism drug and works by 
damaging bacterial DNA, since its reduced form is highly reactive. The rapid reduction of 
nitrofurantoin inside the bacteria causes multiple reactive intermediates to 
attack ribosomal proteins, DNA,  respiration, pyruvate metabolism and other macro 
molecules within the cell[39].  
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Figure 4.11 A) Overall mutations identified by whole-genome sequencing. Mutated genes 
are grouped as their related functions and antibiotics are also classified according to their 
mechanisms of actions.  
 
 Additionally, we identified reproducible and shared mutations from all 
mutations’ data, shown in Figure 4.11B and 4.11C, respectively. If at least two mutations in 
the same or different positions of the same gene were observed, we called as reproducible 
mutations. Especially, mutations on multidrug resistance related genes; such as, marR, acrR 
and mprA were reproducible and also shared. We identified 31 unknown mutation places, 
which were seen at least two times. All of the mutated genes of folic acid metabolism were 
reproducible. However, only gyrA mutations were reproducible in the group of DNA 
replication. 
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Figure 4.11 B) Reproducibly mutated genes involved in resistance. At least two mutations 
at the same position or different position were identifiedon the same gene. 
 
 
Shared mutations are mainly responsible for multidrug resistance phenotype 
because different antibiotic groups have these mutations. For example, transcription related 
marR, acrR, mprA, ompR and fis genes are frequent mutational targets for different groups 
of antibiotics. We identified 7 shared unknown mutations from 31 reproducible unknown 
mutations. Mutations related with folic acid metabolism and DNA replication were not 
shared. By identifying reproducible and shared mutations, we defined hot spot mutation 
positions, some of them were shown in Figure 4.12. 
Figure 4.12 Hot spot mutation
Figure 4.11 C) Shared mutations across different drug classes.
 targets: FusA, fis, ompR an
frameshift mutations.
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d ompF genes. INDEL indicates 
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To further characterize the genotype data, mutations (SNPs or insertion-deletion 
mutations) of strong and weak selections of drug groups were classified.We observed 
totally 370 mutations on strongly selected strains, 24 mutations in weakly selected strains 
and 64 common mutations, shown in Figure 4.13. These mutations were grouped according 
to each drug classes to provide better understanding for the effect of different selection 
powers. As expected, there were more mutations on strongly selected strains than weak 
ones. In most drug groups, strong selection strains had more target specific mutations. For 
example,strongly selected strains of protein synthesis 50S binding inhibitors had mutations 
on the 50S subunit of ribosome genes but weakly selected strains usually had no mutions 
on ribosomal genes except one shared mutation with strong ones.DNA gyrase inhibitors 
had two hot spot mutation targets: gyrA and ompF and these mutated genes were common 
for both selection powers. Similarly, folM, folA and folP mutations were common for both 
strong selection and weak selection of folic acid metabolism inhibitors. DNA gyrase and 
folic acid metabolism inhibitors are very target specific drugs; thus, these results were 
expected.Mutations of cell wall inhibitors were mostly caused by strongly selected 
cefoxitin strains. Evolved strains ofcell wall inhibitors got mutations mostly related with 
membrane functions; such as, ompF, ompR, setB and acrB.Mutations of strong and weak 
selections are shown in Figure 4.14. 
 
 
Figure 4.13 All number of mutations in strong and weak selection strains. 
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Mutations of folic acid biosynthesis inhibitors 
 
 
 
 
 
 
 
 
 
 
Mutations of DNA gyrase inhibitors 
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Mutations of Nitrofurantoin 
 
 
Mutations of cell wall inhibitors 
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Mutations of protein synthesis-50S subunit binding inhibitors 
 
 
Mutations of Aminoglycosides 
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Mutations of protein synthesis-30S subunit binding inhibitors 
 
Figure 4.14 All mutations of each drug groups were classified according to strong and weak 
selections. Black color shows SNP and red color shows indel (frameshift) mutations. 
Straight lines on the gene figures indicate the number of mutations. Genes in the circle are 
related with ribosomal subunits. 
 
 
4.3.2 WGS-Amplification Results 
 
 We also performed amplification analysis to our whole genome sequencing data. 
We defined length threshold as 5000 bp to be conservative enough. To identify regions 
likely to have been duplicated during the evolution process, the number of Illumina 
sequencing reads covering each position of the MG1655 genome were counted using the 
SAMTools software.  
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 We found amplification on three strains: Spiramycin strong resistant strain 2, 
ciprofloxacin weak resistant strain 2 and amikacin weak resistant strain 1. Figure 4.12 
shows amplified regions of these three strains and table 4.3 indicates the positions of 
amplification, length of amplified region and average counts for these regions. In only 
amikacin strain, we observed mutation on amplified region but this was an unknown 
mutation. For other two strains, amplified regions and mutations were not close to each 
other. In amikacin strain, very large region was amplified. When we analyzed the genes 
found in amplified regions, acrA, acrB and acrR genes related with multidrug efflux system 
were identified in these three strains. This could be also explanation for resistance of strain 
spiramycin-strong 2 which does not have a mutation on a region identified as a functional 
gene. Strongly selected spiramycin cultures had same resistance levels at the end of 21 days 
but only one of the strains had mutations on translation related rlmN, rplD and rph genes. 
Second strongly selected spiramycin strain had not a known mutation but had an amplified 
region. Additionaly, some genes related with transportation of molecules and regulation of 
beta lactamase synthesis were determined in these amplified regions; such as: sbmA, 
ampG,tsx, betT and ompT. All of the genes and functions of these genes found in amplified 
regions were indicated in appendix C. 
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Figure 4.15 Amplification results. Strongly selected spiramycin second strain, weak 
selection of ciprofloxacin second strain and amikacin first strain has amplifications 
approximately at the same positions.X-axis shows the whole genome of resistant bacteria 
and y- axis shows average reads of genome. Red lines on the figure indicate mutated genes. 
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Strain name Position Length count 
Spiramycin_S2 318621 10493 183,3 
Spiramycin_S2 331678 5421 178,3 
Spiramycin_S2 343653 5402 182,8 
Spiramycin_S2 389982 10584 197,1 
Spiramycin_S2 429408 6417 179,5 
Spiramycin_S2 449835 5679 178,5 
Spiramycin_S2 479421 7507 178,8 
Spiramycin_S2 557747 8955 188,3 
 
Ciprofloxacin_w2 311848 11185 177,4 
Ciprofloxacin_w2 390681 7152 174,3 
Ciprofloxacin_w2 560749 5700 164,1 
Ciprofloxacin_w2 569504 5366 166,4 
Ciprofloxacin_w2 579044 5827 173,9 
 
Amikacin_w1 317334 20504 178,3 
Amikacin_w1 343388 6069 175,8 
Amikacin_w1 360880 5298 165 
Amikacin_w1 419295 7442 172,2 
Amikacin_w1 428808 7981 169,9 
Amikacin_w1 447529 8165 172,5 
Amikacin_w1 456002 10259 171,7 
Amikacin_w1 478002 11729 174,9 
Amikacin_w1 499724 5956 169,3 
Amikacin_w1 526336 6239 175,7 
Amikacin_w1 535725 5845 163,5 
Amikacin_w1 556440 10764 176,7 
 
Table 4.3 Amplication table. Amplification positions, length of each amplified regions and 
average counts of this regions are indicated. 
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5. DISCUSSION 
 
 
Antibiotics are nanometer sized small molecules that can cure bacterial infections 
and the discovery of the first antibiotic compound by Alexander Fleming is a milestone in 
modern medicine However, use of antibiotics gave rise to resistance problem because 
bacterial populations have a significant capacity to deal with stressful conditions and 
antibiotics act as selective agent for resistant strains. Hence, antibiotic resistance is a global 
public health threat. As indicated in the introduction part, resistance can be intrinsic or 
acquired and there are many mechanisms for resistance; such as: enzymatic destruction or 
modification of the antibiotic by resistant bacteria, increase activation of efflux pumps and 
replacement or modification of the antibiotic target. Multi drug resistance and cross 
resistance are very important parts of antibiotic resistance because today we have a list of 
organisms resistant to many different antibiotics in both hospitals and the community. Over 
the years, many attempts have been made in the medical fields to resolve the mentioned 
problem. The most widely applied proposals to this problem are developing novel 
antibiotics and using the existing ones more effectively. The number of new antibiotics has 
declined significantly in recent years because of financial and natural constraints. Thus, the 
effective use of available drugs seems to be the most reasonable option. In this respect, 
applications of drug combinations have been mostly suggested. Due to lack of knowledge 
on bacterial drug resistance at the molecular and population levels, there is a growing need 
of knowledge on phenotypic and genotypic characterization of bacteria while developing 
resistance to antibiotics. 
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In this project, the main aim was designing and testing novel strategies for 
minimizing the rate of evolution of drug resistance. Through integration of phenotypic 
analysis of resistant strains and sequencing, we were able to give an idea of the 
evolutionary pathways for different classes of antibiotics, cross resistance between twenty 
two drugs, general patterns of cross resistance in drug groups and reasons for resistance 
mechanisms: mutated genes and amplified regions of evolved strains. In order to 
understand the mechanisms of bacterial resistance against drugs, we performed long term 
adaptation experiments by using classical methods and we phenotyped and genotyped 
evolved strains. For phenotypic characterization, we searched for cross resistance between 
drugs. Cross resistance was especially between the drugs of same classes and we observed 
this phenomenon for all drug class except protein synthesis, 30S inhibitors. This can be 
because of different mutations. Drug specific and shared mutations were observed in this 
study. When we combined our phenotypic analysis with whole genome sequencing, we got 
lots of knowledge about antibiotic behaviors.  
 
Reciprocal evolution was observed mostly within drug classes, but not across 
different classes. However, there were some exceptions seen in protein synthesis 30S 
subunit binding inhibitors; such as: DOX resistant strains evolved resistance to TET but we 
did not observe the opposite. Mutations on AcrR and marR genes may explain this result 
since these two genes are related with multi drug resistance. These results were a bit of 
surprise but when we searched all mutations, we generally understood reasons. For 
example, ampicillin resistant strains became resistant to tetracycline and spiramycin mostly 
because they got acrB and envZ mutations. There are some unexplained results of our study 
and we still continue to analysis our genotype data. 
 
Another interesting result of our research was evolved strains of aminoglycoside 
group antibiotics showed increased susceptibility towards most of the other drugs. When 
we looked into mutations, we realized that aminoglycosides have trkH mutated gene. Most 
of these mutations were on the same place and caused same amino acid substitution. TrkH 
is a potassium transporter and mutation on this gene could be a reason for increased 
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sensitivity. Additionally, most of the evolved strains, except gyrase inhibitors, behaved as 
wild type to lomefloxacin, which is also a kind of gyrase inhibitor.  
 
The bacterial evolution patterns do not resemble each other. Spiramycin evolved 
strains get same amount of resistance at the end of evolution experiment. According to 
whole genome sequencing, first strong selection strain of spiramycin get mutations on 
translation related genes but second strong selection strain of spiramycin did not get any 
known mutation. Instead of mutation, this strain had amplified region (duplication) in its 
genome. However, mutation places of first strain are quite far away from amplified regions 
of second strain. AcrA,acrB and acrR genes, multidrug resistance genes, in the amplified 
regions was found. These multi drug efflux system related genes can be an explanation for 
cross resistance behavior of spiramycin second strong selection strain to other drugs. 
 
Evolved strains of folic acid inhibitors had mutations on folic acid biosynthesis 
pathway; such as, folA, folX, folP and folM. We expected to find mutations on DHFR 
regions but mutation on folM was surprising since it is dihydrofolate reductase isozyme.  
 
We observed many mutations on strongly selected strains of cefoxitin. ~200 
mutations were count for these strains but weak selection strains only have two or three 
mutations. These strains got mutations on their DNA polymerases. They both have 
mutations on dnaE and dnaX genes, DNA polymerase (III) subunit. May be these two 
mutations resulted in many replication errors and many errors cause too many mutations on 
various genes.  We are not sure about what happened in the cell so we will repeat evolution 
experiment for cefoxitin as twenty replicates: 10 replicates for weak selection and 10 
replicates for strong selection to be sure about results. If we see too many mutations again 
in the last day cultures, we will sequence evolved strains from different days to understand 
which mutation on a specific gene causes many mutations and mutation orders. In our 
experiment design, we only sequenced cultures of last day so we could not understand 
mutation order; therefore, we should make sequencing from various days of the culture for 
cefoxitin.  
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Additionally, we identified mutations according to selection powers for each drug 
classes. Much more mutations were observed in strongly selected strains than weakly 
selected strains. There were also many shared mutations between strong and weak 
selections. When we searched mutations carefully, we observed that strong selection strains 
mostly had target specific mutations. For example, strongly selected strains of protein 
synthesis 50S subunit binding inhibitors had mutations in the 50S subunit related genes and 
one shared mutation in this subunit; however , we did not observe such specific mutations  
in the weakly selected strains. Interestingly, mutations in the 30S subunit related genes 
were not observed frequently. Only two 30S subunit genes: rpsL and rpsE were mutated in 
all of the streptomycin and spectinomycin, respectively. Small size of 30S subunit when 
compared with 50S may be an explanation for this genotype. Additionally, 31 reproducible 
and 7 shared unknown mutation were identified but we do not know anything about 
functions of these genes. 7 shared unknown mutation places can be thought as hot spot 
target places for mutations because 2 of these unknown mutation places were seen 9 and 8 
times, respectively across the different antibiotic groups. There can be an undiscovered 
gene in that region related with multiple drug resistance. 
 
Lastly, we want to see whether there is a relationship between cross resistance and 
drug interactions. We used data set from Yeh et al. (2006) to make comparison shown in 
Figure 5.1.  We could not see general pattern since our cross resistance is not reciprocal. 
Interactions between drugs have one direction but cross resistance has two directions. For 
instance; evolved strains of chloramphenicol are resistant to tetracycline but evolved strains 
of tetracycline became more susceptible to chloramphenicol. According to Yeh et al (2006), 
interaction between chloramphenicol and tetracycline is antagonism so we cannot make 
generalization about interactions and cross resistance. However, if we observe reciprocal 
cross resistance, we can look for drug interactions. We observed reciprocal resistance 
mostly between same drug classes, especially DNA gyrase inhibitors, cell wall inhibitors 
and aminoglycosides, and we searched interactions within same classes of antibiotics. For 
example, DNA gyrase inhibitors had reciprocal cross resistance and we searched for 
interaction types between these three antibiotics (ciprofloxacin, lomefloxacin and nalidixic 
acid) and observed that there is an additive interaction between ciprofloxacin and 
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lomefloxacin, nalidixic acid and ciprofloxacin, lomefloxacin and nalidixic acid. 
Additionally, there is a reciprocal cross resistance between all cell wall inhibitors 
(piperacillin, ampicillin and cefoxitin) and we observed a synergistic interaction among 
these three drugs. For aminoglycosides, there is also synergistic interaction between them. 
Then, we searched for antibiotics showing reciprocal cross resistance and interactions 
between them. There is a reciprocal cross resistance between tetracycline and ciprofloxacin 
and interaction between these two drugs is antagonistic. We could not make a general 
assumption for cross resistance and drug interactions. 
 
 
 
Figure 5.1 Systematic measurements of pairwise interactions between antibiotics. Growth 
measurements and classiﬁcation of interaction for all pairwise combinations of drugs X and 
Y. Synergistic interactions are shown red-pink, antagonistic buffering is green- light green, 
antagonistic suppression is blue and additive is white color. Cases that do not fall into any 
of these categories are labeled inconclusive: gray background[40]. 
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6. CONCLUSION 
 
Antibiotic resistance is a serious problem in hospitals and in community; therefore, 
understanding the evolutionary biology and genomics of resistance can give information 
about therapeutic strategies. Antibiotic resistance can evolve through accumulation of 
mutations. Indeed, only one mutation can be sufficient for bacteria to overcome antibiotic 
induced stress. In this project, microbial evolution techniques, phenotypic measurements 
and whole genome sequencing were successfully used to reveal phenotypic and genotypic 
changes that cause to resistance. 
In summary, we designed an evolution experiment for twenty two drugs and 
observed evolution of bacteria for 21 days. After generation of 88 evolved strains, we 
performed phenotypic and genotypic characterization for these strains to investigate cross 
resistance between antibiotics. As a result of this study, same groups of antibiotics showed 
increased cross resistance for each other. We could not find relationship between drug 
interactions and cross resistance. Lastly, we identified mutations and amplifications of all 
evolved strains. When we combine our phenotypic and genotypic data, we may give some 
recommendations for therapeutic implications. We learned that reciprocal cross resistance 
is common in same drug classes so we should avoid choosing drugs from same classes in 
multidrug treatments. Antibiotics causing mutations on multidrug efflux pump related 
genes should not be used in long time treatments. We can choose drugs according to 
mutation pathways for multiple drug treatments. 
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7.FUTURE WORK 
 
 
In the light of the results reported here, we would like to suggest the some future 
work. According to our phenotypic measurements, mathematical pair wise scores may be 
given for cross resistance matrix. By this way, we can score drug behaviors and identify the 
group of an unknown drug by using our master plate and cross resistance experiments. 
General pattern of mutations can be examined by analyzing cross resistance data more 
carefully according to sequencing data. In this study, we performed whole genome 
sequencing and revealed mutations and functions of mutated genes. However we did not 
search the effect of mutations in transcriptional level. Expression levels of mutated genes 
may be searched as future work.Also, in our study, mutations occurred naturally but we do 
not know whether it will be different with site directed mutagenesis or not. Therefore; well-
known mutations on specific genes may be carried out again with site directed mutagenesis 
and the differences can be compared. Because of the very interesting genotypic results in 
cefoxitin strains, evolution experiments for cefoxitin will be repeated with twenty replicates 
to make sure about increased number of mutations and sequencing will be performed from 
different days to analyze the mutation pathway. According to our phenotype data, 
aminoglycosides got resistant to each other but they became more susceptible to other 
antibiotic classes. Genotype of aminoglycosides should be analyzed more carefully. Lastly 
and most importantly, specific drug pairs can be identified from our data for alternative 
treatment strategies and these drug pairs can be tested for both treatment and resistance. 
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APPENDIX 
 
Appendix A: All Graphs for Representative Colony Selection 
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Appendix B: Whole Genome Sequencing – Mutations 
 
636102 [ybdO] NP_415136.1 putative DNA-binding transcriptional regulator 
1273685 [ychO] NP_415738.2 putative invasin 
3204885 [ttdA] NP_417533.1 L-tartrate dehydratase, alpha subunit 
1644077 [ydfV] NP_416083.1 Qin prophage; putative protein 
3856156 [yidJ] NP_418134.1 putative sulfatase/phosphatase 
2569257 [eutE] NP_416950.1 aldehyde oxidoreductase, ethanolamine utilization protein 
2890985 [ygcN] NP_417246.4 putative oxidoreductase with FAD/NAD(P)-binding domain 
504406 [ushA] NP_415013.1 bifunctional UDP-sugar hydrolase/5'-nucleotidase 
4044187 [yihG] NP_418299.1 inner membrane protein, Predicted acyltransferas 
4400960 [hflK] NP_418595.1 modulator for HflB protease specific for phage lambda cII repressor 
1065805 [agp] NP_415522.1 glucose-1-phosphatase/inositol phosphatase 
1708344 [rsxG] NP_416148.1 electron transport complex protein required for the reduction of SoxR 
1109415 [opgG] NP_415566.1 osmoregulated periplasmic glucan (OPG) biosynthesis periplasmic protein 
4451975 [yjfF] NP_418652.2 putative sugar transporter subunit: membrane component of ABC superfamily 
2211060 [yehU] NP_416630.1 putative sensory kinase in two-component system with YehT, inner membrane protein 
3814791 [yicC] NP_418101.1 conserved protein, UPF0701 family 
1617422 [marR] NP_416047.4 DNA-binding transcriptional repressor of multiple antibiotic resistance 
3178101 [ygiB] NP_417509.3 conserved protein, UPF0441 family 
985568 [ompF] NP_415449.1 outer membrane porin 1a (Ia;b;F) 
3994178 [yigA] NP_418255.1 conserved protein, DUF484 family 
2462895 [mlaA] NP_416848.1 ABC transporter maintaining OM lipid asymmetry, OM lipoprotein component 
3450110 [rplD] NP_417778.1 50S ribosomal subunit protein L4 
1411301 [ydaQ] NP_415862.4 Rac prophage; conserved protein 
4415505 [yjfP] NP_418611.1 acyl CoA esterase 
3091191 [yqgE] NP_417423.4 hypothetical protein 
4349471 
[dcuS] NP_418549.1 sensory histidine kinase in two-component regulatory system with DcuR,  
regulator of anaerobic fumarate respiration 
1842573 [ynjI] NP_416276.4 inner membrane protein 
2188932 [yehB] NP_416612.1 putative outer membrane protein 
1372108 [ycjO] NP_415827.1 putative sugar transporter subunit: membrane component of ABC superfamily 
4369590 [groL] NP_418567.1 Cpn60 chaperonin GroEL, large subunit of GroESL 
1417204 [ydaF] NP_415872.2 Rac prophage; putative protein 
1933726 [zwf] NP_416366.1 glucose-6-phosphate 1-dehydrogenase 
3448680 [rplB] NP_417776.1 50S ribosomal subunit protein L2 
578086 [borD] NP_415089.1 DLP12 prophage; predicted lipoprotein 
3219786 [ebgR] NP_417546.1 DNA-binding transcriptional repressor 
395944 [sbmA] NP_414911.1 microcin B17 transporter 
2294807 [ccmB] NP_416704.1 heme exporter subunit 
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571753 [ybcN] NP_415079.1 DLP12 prophage; putative protein 
4477393 [yjgM] YP_026287.1 putative acetyltransferase 
3469708 [fusA] NP_417799.1 protein chain elongation factor EF-G, GTP-binding 
4025993 [fadA] YP_026272.1 3-ketoacyl-CoA thiolase (thiolase I) 
529391 [selU] NP_415036.1 tRNA 2-selenouridine synthase, selenophosphate-dependent 
3103465 [mltC] NP_417438.2 membrane-bound lytic murein transglycosylase C 
2337195 [gyrA] NP_416734.1 DNA gyrase (type II topoisomerase), subunit A 
2217053 [osmF] NP_416635.1 putative transporter subunit: periplasmic-binding component of ABC superfamily 
2587454 [acrD] NP_416965.1 aminoglycoside/multidrug efflux system 
1784986 [ppsA] NP_416217.1 phosphoenolpyruvate synthase 
3443179 [rpsE] NP_417762.1 30S ribosomal subunit protein S5 
1617223 [marR] NP_416047.4 DNA-binding transcriptional repressor of multiple antibiotic resistance 
1721019 [ydhK] NP_416162.1 putative efflux protein (PET) component of YdhJK efflux pump 
1812602 [katE] YP_025308.1 catalase HPII, heme d-containing 
492388 [dnaX] NP_415003.1 DNA polymerase III/DNA elongation factor III, tau and gamma subunits 
3393629 [yhdP] YP_026208.1 conserved membrane protein, predicted transporter 
404757 [proC] NP_414920.1 pyrroline-5-carboxylate reductase, NAD(P)-binding 
3450199 [rplD] NP_417778.1 50S ribosomal subunit protein L4 
3938325 [hsrA] NP_418210.1 putative multidrug or homocysteine efflux system 
916553 [ybjD] NP_415397.1 conserved protein with nucleoside triphosphate hydrolase domain 
3161196 [plsC] NP_417490.1 1-acyl-sn-glycerol-3-phosphate acyltransferase 
485003 [acrR] NP_414997.1 DNA-binding transcriptional repressor 
3146232 [gpr] NP_417474.1 L-glyceraldehyde 3-phosphate reductase 
2211749 [yehU] NP_416630.1 putative sensory kinase in two-component system with YehT, inner membrane protein 
1687419 [manA] NP_416130.3 mannose-6-phosphate isomerase 
4215787 [aceA] NP_418439.1 isocitrate lyase 
1760687 [sufB] NP_416198.2 component of SufBCD Fe-S cluster assembly scaffold 
1113310 [msyB] NP_415569.4 multicopy suppressor of secY and secA 
2551265 [hemF] NP_416931.1 coproporphyrinogen III oxidase 
1445666 [feaB] NP_415903.4 phenylacetaldehyde dehydrogenase 
2278304 [rsuA] NP_416688.1 16S rRNA pseudouridine(516) synthase 
3472447 [rpsL] NP_417801.1 30S ribosomal subunit protein S12 
3997256 [uvrD] NP_418258.1 DNA-dependent ATPase I and helicase II 
388323 [hemB] NP_414903.4 5-aminolevulinate dehydratase (porphobilinogen synthase) 
912965 [hcp] NP_415394.4 hybrid-cluster [4Fe-2S-2O] protein in anaerobic terminal reductases 
2931496 [fucA] NP_417280.1 L-fuculose-1-phosphate aldolase 
1553065 [maeA] NP_415996.2 malate dehydrogenase, (decarboxylating, NAD-requiring) (malic enzyme) 
4031625 [trkH] YP_026273.1 potassium transporter 
1294996 
[adhE] NP_415757.1 fused acetaldehyde-CoA dehydrogenase/ 
iron-dependent alcohol dehydrogenase/pyruvate-formate lyase deactivase 
2670868 [hcaD] NP_417037.1 phenylpropionate dioxygenase, ferredoxin reductase subunit 
2119476 [wcaJ] NP_416551.1 colanic biosynthesis UDP-glucose lipid carrier transferase 
2160107 [mdtD] NP_416581.1 putative arabinose efflux transporter 
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1195455 [icd] NP_415654.1 e14 prophage; isocitrate dehydrogenase, specific for NADP+ 
2360177 [rhmR] NP_416751.1 putative DNA-binding transcriptional regulator for the rhm operon 
2133543 [wzc] NP_416564.4 protein-tyrosine kinase 
883442 [mdfA] NP_415363.1 multidrug efflux system protein 
1386108 [tyrR] NP_415839.1 DNA-binding transcriptional dual regulator, tyrosine-binding 
1617374 [marR] NP_416047.4 DNA-binding transcriptional repressor of multiple antibiotic resistance 
1186811 [ycfD] NP_415646.4 cupin superfamily protein 
861224 [ybiW] NP_415344.1 putative pyruvate formate lyase 
2809265 [mprA] NP_417169.1 DNA-binding transcriptional repressor of microcin B17 synthesis and multidrug efflux 
4514825 [fecR] NP_418712.1 KpLE2 phage-like element; transmembrane signal transducer for ferric citrate transport 
4224788 [metH] NP_418443.1 homocysteine-N5-methyltetrahydrofolate transmethylase, B12-dependent 
3776879 [lldP] NP_418060.1 L-lactate permease 
2462896 [mlaA] NP_416848.1 ABC transporter maintaining OM lipid asymmetry, OM lipoprotein component 
396841 [sbmA] NP_414911.1 microcin B17 transporter 
3406003 [panF] NP_417724.4 pantothenate:sodium symporter 
2073907 [yeeR] NP_416505.2 CP4-44 prophage; predicted membrane protein 
2872282 [cysN] NP_417231.1 sulfate adenylyltransferase, subunit 1 
2307723 
[ada] NP_416717.1 fused DNA-binding transcriptional dual regulator/ 
O6-methylguanine-DNA methyltransferase 
837437 [ybiI] NP_415324.1 DksA-type zinc finger protein 
578815 [ybcV] NP_415090.2 DLP12 prophage; putative protein 
1091498 
[pgaA] NP_415543.1 biofilm adhesin polysaccharide PGA secretin;  
OM porin; poly-beta-1,6-N-acetyl-D-glucosamine export protein 
911406 [hcp] NP_415394.4 hybrid-cluster [4Fe-2S-2O] protein in anaerobic terminal reductases 
3968099 [wzzE] NP_418232.2 Entobacterial Common Antigen (ECA) polysaccharide chain length modulation protein 
345354 [yahN] NP_414862.1 amino acid exporter for proline, lysine, glutamate, homoserine 
888983 [ybjL] NP_415368.1 putative transporter 
1773282 [aroD] NP_416208.1 3-dehydroquinate dehydratase 
1955486 [torY] NP_416387.1 TMAO reductase III (TorYZ), cytochrome c-type subunit 
2477192 [dsdX] NP_416866.1 D-serine permease 
802885 [ybhJ] NP_415292.2 putative hydratase 
1406309 [ydaN] NP_415858.1 putative Zn(II) transporter 
305436 [ecpD] NP_414824.1 putative receptor 
473964 [tesB] NP_414986.1 acyl-CoA thioesterase II 
1234632 [fadR] NP_415705.1 DNA-binding transcriptional dual regulator of fatty acid metabolism 
2310640 [ompC] NP_416719.1 outer membrane porin protein C 
2204671 [yehM] NP_416624.1 hypothetical protein 
2643570 
[pbpC] NP_417014.1 penicillin-binding protein PBP1C murein transglycosylase;  
inactive transpeptidase domain 
2200139 [yehI] NP_416621.1 hypothetical protein 
2073784 [yeeR] NP_416505.2 CP4-44 prophage; predicted membrane protein 
482636 [acrB] NP_414995.1 multidrug efflux system protein 
793325 [modE] NP_415282.1 DNA-binding transcriptional repressor for the molybdenum transport operon modABC 
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2097421 [ugd] NP_416532.1 UDP-glucose 6-dehydrogenase 
3443181 [rpsE] NP_417762.1 30S ribosomal subunit protein S5 
4275919 [soxR] NP_418487.1 DNA-binding transcriptional dual regulator, Fe-S center for redox-sensing 
4589958 [tsr] NP_418775.1 methyl-accepting chemotaxis protein I, serine sensor receptor 
2809146 [mprA] NP_417169.1 DNA-binding transcriptional repressor of microcin B17 synthesis and multidrug efflux 
2865722 [nlpD] NP_417222.1 activator of AmiC murein hydrolase activity, lipoprotein 
985631 [ompF] NP_415449.1 outer membrane porin 1a (Ia;b;F) 
3148003 [yghA] NP_417476.1 putative oxidoreductase 
4312125 [yjdP] YP_026281.1 hypothetical protein 
3524151 [nudE] NP_417856.1 adenosine nucleotide hydrolase; substrates include Ap3A, Ap2A, ADP-ribose, NADH 
1671998 [tqsA] NP_416118.1 pheromone AI-2 transporter 
648706 [citF] NP_415148.1 citrate lyase, citrate-ACP transferase (alpha) subunit 
986178 [ompF] NP_415449.1 outer membrane porin 1a (Ia;b;F) 
206222 [dnaE] NP_414726.1 DNA polymerase III alpha subunit 
2443462 [yfcA] NP_416830.1 inner membrane protein, UPF0721 family 
3534600 [ompR] NP_417864.1 DNA-binding response regulator in two-component regulatory system with EnvZ 
1174912 [lolC] NP_415634.1 lipoprotein-releasing system transmembrane protein 
468200 
[mdlA] NP_414982.1 fused predicted multidrug transporter subunits of ABC superfamily:  
ATP-binding components 
3483722 [yhfA] NP_417815.1 conserved protein, OsmC family 
2204640 [yehM] NP_416624.1 hypothetical protein 
1347175 [yciW] NP_415803.2 putative oxidoreductase 
3322850 [folP] NP_417644.4 7,8-dihydropteroate synthase 
3438945 [rpoA] NP_417754.1 RNA polymerase, alpha subunit 
3298314 [yhbS] NP_417625.1 putative acyltransferase with acyl-CoA N-acyltransferase domain 
985734 [ompF] NP_415449.1 outer membrane porin 1a (Ia;b;F) 
1181136 [potD] NP_415641.1 polyamine transporter subunit 
3038287 [fldB] NP_417371.1 flavodoxin 2 
4455000 [mpl] NP_418654.1 UDP-N-acetylmuramate:L-alanyl-gamma-D-glutamyl-meso-diaminopimelate ligase 
1890900 [yoaA] NP_416322.1 conserved protein with nucleoside triphosphate hydrolase domain 
4204941 
[purH] NP_418434.1 fused IMP cyclohydrolase/ 
phosphoribosylaminoimidazolecarboxamide formyltransferase 
1663606 [clcB] NP_416109.2 H(+)/Cl(-) exchange transporter 
55879 [lptD] NP_414596.1 LPS assembly OM complex LptDE, beta-barrel component 
1946940 [aspS] NP_416380.1 aspartyl-tRNA synthetase 
3409267 [dusB] NP_417726.1 tRNA-dihydrouridine synthase B 
3928520 [ravA] NP_418202.4 fused predicted transcriptional regulator: sigma54 activator protein/conserved protein 
1715421 [pdxH] NP_416155.1 pyridoxine 5'-phosphate oxidase 
3786341 [yibQ] NP_418071.4 putative polysaccharide deacetylase 
2970274 
[tas] NP_417311.1 putative oxidoreductase, NADP(H)-dependent aldo-keto reductase;  
suppresses tyrosine requirement of tyrA14 O6 strain 
847046 [glnH] NP_415332.1 glutamine transporter subunit 
2722072 [pssA] NP_417080.4 phosphatidylserine synthase (CDP-diacylglycerol-serine O-phosphatidyltransferase) 
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3915559 [atpG] NP_418189.1 F1 sector of membrane-bound ATP synthase, gamma subunit 
44460 [fixC] NP_414585.1 putative oxidoreductase with FAD/NAD(P)-binding domain 
3876752 [gyrB] YP_026241.1 DNA gyrase, subunit B 
1744956 [ydhR] NP_416182.1 putative monooxygenase 
3470224 [fusA] NP_417799.1 protein chain elongation factor EF-G, GTP-binding 
1747253 [ydhT] NP_416184.1 hypothetical protein 
2918564 [gudX] NP_417268.1 glucarate dehydratase-related protein, substrate unknown 
268887 [perR] NP_414788.1 CP4-6 prophage; predicted DNA-binding transcriptional regulator 
2186577 [yehB] NP_416612.1 putative outer membrane protein 
3081120 [speB] NP_417412.1 agmatinase 
445555 [yajR] NP_414961.4 putative transporter 
2470630 [yfdN] NP_416858.1 CPS-53 (KpLE1) prophage; putative protein 
384852 [tauA] NP_414899.2 taurine transporter subunit 
54342 [surA] NP_414595.1 peptidyl-prolyl cis-trans isomerase (PPIase) 
703318 [nagE] NP_415205.1 fused N-acetyl glucosamine specific PTS enzyme: IIC, IIB, and IIA components 
3469576 [fusA] NP_417799.1 protein chain elongation factor EF-G, GTP-binding 
3160208 
[ftsP] NP_417489.1 septal ring component that protects the divisome from stress;  
multicopy suppressor of ftsI(Ts) 
1883390 [yeaW] NP_416316.1 putative 2Fe-2S cluster-containing protein 
4413191 
[aidB] NP_418608.6 DNA alkylation damage repair protein; flavin-containing DNA binding protein,  
weak isovaleryl CoA dehydrogenase 
3191310 [yqiK] NP_417523.1 PHB family membrane protein, function unknown 
2392778 [nuoL] NP_416781.1 NADH:ubiquinone oxidoreductase, membrane subunit L 
829057 
[ybhG] NP_415316.1 putative membrane fusion protein (MFP) component of efflux pump, 
 membrane anchor 
4556529 [iadA] NP_418748.1 isoaspartyl dipeptidase 
50273 [folA] NP_414590.1 dihydrofolate reductase 
1087859 
[pgaB] NP_415542.1 poly-beta-1,6-N-acetyl-D-glucosamine (PGA) N-deacetylase;  
deacetylase required for biofilm adhesin polysaccharide PGA export;  
1195468 [icd] NP_415654.1 e14 prophage; isocitrate dehydrogenase, specific for NADP+ 
1347477 [yciW] NP_415803.2 putative oxidoreductase 
433516 
[ribD] NP_414948.1 fused diaminohydroxyphosphoribosylaminopyrimidine deaminase and  
5-amino-6-(5-phosphoribosylamino) uracil reductase 
2764951 [rnlA] NP_417119.1 CP4-57 prophage; RNase LS 
3744558 
[yiaO] NP_418036.1 L-dehydroascorbate transporter, periplasmic binding protein for  
TRAP (TRipartite ATP-independent Periplasmic) family transport> 
3867078 [yidR] NP_418144.3 hypothetical protein 
2935304 [fucI] NP_417282.1 L-fucose isomerase 
952105 [pflB] NP_415423.1 pyruvate formate lyase I 
2418438 [yfcF] NP_416804.1 glutathione S-transferase 
49884 [folA] NP_414590.1 dihydrofolate reductase 
1207007 [stfP] NP_415672.1 e14 prophage; putative protein 
1310586 [yciB] NP_415770.1 putative inner membrane protein 
693849 [miaB] NP_415194.1 tRNA-i(6)A37 methylthiotransferase 
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2775583 [ypjF] NP_417133.1 CP4-57 prophage; toxin of the YpjF-YfjZ toxin-antitoxin system 
102057 [murC] NP_414633.1 UDP-N-acetylmuramate:L-alanine ligase 
1002941 [ycbV] NP_415463.2 putative fimbrial-like adhesin protein 
2245623 [lysP] NP_416661.1 lysine transporter 
4432824 [cpdB] NP_418634.1 2':3'-cyclic-nucleotide 2'-phosphodiesterase 
2070411 [flu] YP_026164.1 CP4-44 prophage; antigen 43 (Ag43) phase-variable biofilm formation autotransporter 
2203844 [yehM] NP_416624.1 hypothetical protein 
2877629 [ygbT] NP_417235.1 multifunctional endonuclease Cas1, CRISPR adaptation protein; DNA repair enzyme 
3080414 
[loiP] NP_417411.2 Phe-Phe periplasmic metalloprotease, OM lipoprotein; low salt-inducible; 
 heat shock protein that binds Era 
3120256 [glcB] NP_417450.1 malate synthase G 
1679783 [ydgC] NP_416124.1 inner membrane protein, GlpM family 
1871805 [yeaK] NP_416301.1 hypothetical protein 
137377 [cueO] NP_414665.1 multicopper oxidase (laccase) 
2687816 
[glrK] NP_417051.2 sensor protein kinase regulating glmY sRNA in two-component system  
with response regulator GlrR 
3064489 [ygfI] NP_417396.4 putative DNA-binding transcriptional regulator 
4251293 [ubiA] NP_418464.1 p-hydroxybenzoate octaprenyltransferase 
3830912 [yicI] NP_418113.1 putative alpha-glucosidase 
3125042 [glcD] NP_417453.1 glycolate oxidase subunit, FAD-linked 
3448974 [rplB] NP_417776.1 50S ribosomal subunit protein L2 
1900832 [manX] NP_416331.1 fused mannose-specific PTS enzymes: IIA component/IIB component 
3177594 [tolC] NP_417507.2 transport channel 
550209 [ybcF] NP_415054.1 putative carbamate kinase 
4131373 [metF] NP_418376.1 5,10-methylenetetrahydrofolate reductase 
3136911 [yghU] NP_417463.4 putative S-transferase 
1257441 [pth] NP_415722.1 peptidyl-tRNA hydrolase 
1187003 [ycfD] NP_415646.4 cupin superfamily protein 
1642279 [ydfU] NP_416078.4 Qin prophage; putative protein 
4275121 [soxS] NP_418486.1 DNA-binding transcriptional dual regulator 
12226 [dnaK] NP_414555.1 chaperone Hsp70, co-chaperone with DnaJ 
1973718 [motB] NP_416403.1 protein that enables flagellar motor rotation 
2314647 [rcsB] NP_416721.1 DNA-binding response regulator in two-component regulatory system  
1428751 [stfR] NP_415890.2 Rac prophage; predicted tail fiber protein 
3001451 [xdhB] NP_417343.1 xanthine dehydrogenase, FAD-binding subunit 
4275928 [soxR] NP_418487.1 DNA-binding transcriptional dual regulator, Fe-S center for redox-sensing 
3348148 [elbB] NP_417676.2 isoprenoid biosynthesis protein with amidotransferase-like domain 
2229437 [yohK] NP_416647.1 inner membrane protein, LrgB family 
701000 [nagA] NP_415203.1 N-acetylglucosamine-6-phosphate deacetylase 
3485248 [yhfK] NP_417817.2 conserved inner membrane protein 
1195470 [icd] NP_415654.1 e14 prophage; isocitrate dehydrogenase, specific for NADP+ 
396573 [sbmA] NP_414911.1 microcin B17 transporter 
74244 [thiP] NP_414609.1 fused thiamin transporter subunits of ABC superfamily: membrane components 
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3249422 [yqjG] NP_417573.1 putative S-transferase 
452251 [ampG] NP_414967.1 muropeptide transporter 
959520 [ycaL] NP_415429.2 putative peptidase with chaperone function 
2836876 [ascG] NP_417194.2 DNA-binding transcriptional repressor 
260982 [proA] NP_414778.1 gamma-glutamylphosphate reductase 
1792999 [btuC] NP_416226.1 vitamin B12 transporter subunit: membrane component of ABC superfamily 
3317785 [argG] NP_417640.1 argininosuccinate synthetase 
1250379 [dhaR] NP_415719.2 DNA-binding transcription activator of the dhaKLM operon 
3534585 [ompR] NP_417864.1 DNA-binding response regulator in two-component regulatory system with EnvZ 
2464658 [intS] NP_416850.1 CPS-53 (KpLE1) prophage; predicted prophage CPS-53 integrase 
4470201 [pyrB] NP_418666.1 aspartate carbamoyltransferase, catalytic subunit 
1817195 [chbR] NP_416249.1 repressor of chb operon for N,N'-diacetylchitobiose utilization 
3318300 [yhbX] NP_417641.4 putative hydrolase, inner membrane 
2209775 [yehS] NP_416628.1 conserved protein, DUF1456 family 
3310080 [truB] NP_417635.1 tRNA pseudouridine(55) synthase 
1431277 [pinR] NP_415892.1 Rac prophage; predicted site-specific recombinase 
1354665 [sapA] NP_415810.1 antimicrobial peptide transport ABC transporter periplasmic binding protein 
3868548 [dgoT] NP_418146.4 D-galactonate transporter 
719983 [ybfK] YP_001165310.1 hypothetical protein 
929058 
[cydD] NP_415407.1 fused glutathione, cysteine exporter subunits of ABC superfamily:  
membrane component/ATP-binding component 
3032847 [lysS] NP_417366.1 lysine tRNA synthetase, constitutive 
107453 [lpxC] NP_414638.1 UDP-3-O-acyl N-acetylglucosamine deacetylase 
983426 [ycbL] NP_415447.1 putative metal-binding enzyme 
2921998 [yqcC] NP_417272.1 hypothetical protein 
210681 [ldcC] NP_414728.1 lysine decarboxylase 2, constitutive 
564204 [intD] NP_415069.1 DLP12 prophage; predicted integrase 
1060972 [torA] NP_415517.1 trimethylamine N-oxide (TMAO) reductase I, catalytic subunit 
3499212 [frlA] NP_417829.2 putative fructoselysine transporter 
3443427 [rplR] NP_417763.1 50S ribosomal subunit protein L18 
3813953 [rph] YP_001491547.1 defective ribonuclease PH 
1723265 [ydhF] YP_025305.1 putative oxidoreductase 
3198582 [ygiF] NP_417526.1 putative adenylate cyclase 
329967 [betT] NP_414848.1 choline transporter of high affinity 
3315876 [rimP] NP_417639.6 ribosome maturation factor for 30S subunits 
2913808 [barA] NP_417266.1 hybrid sensory histidine kinase, in two-component regulatory system with UvrY 
1107598 
[opgC] NP_415565.1 membrane protein required for succinylation of  
osmoregulated periplasmic glucans (OPGs) 
3470425 [fusA] NP_417799.1 protein chain elongation factor EF-G, GTP-binding 
3129698 [yghQ] YP_026192.1 putative inner membrane protein 
4136733 [gldA] NP_418380.4 glycerol dehydrogenase, NAD 
1683342 [fumC] NP_416128.1 fumarate hydratase (fumarase C),aerobic Class II 
587340 [nfrA] NP_415100.1 bacteriophage N4 receptor, outer membrane subunit 
 94 
 
4268514 [yjbQ] NP_418480.1 thiamin phosphate synthase 
2436526 [flk] NP_416824.1 putative flagella assembly protein 
3380750 [degS] NP_417702.1 serine endoprotease, periplasmic 
2529722 [cysZ] NP_416908.1 putative inner membrane protein 
870059 [gsiB] NP_415351.1 glutathione periplasmic binding protein, ABC superfamily transporter 
3858913 [yidL] NP_418136.2 putative transcriptional regulator, AraC family 
4395634 [mutL] NP_418591.1 methyl-directed mismatch repair protein 
2419381 
[folX] NP_416806.1 D-erythro-7,8-dihydroneopterin triphosphate 2'-epimerase and  
dihydroneopterin aldolase 
3876781 [gyrB] YP_026241.1 DNA gyrase, subunit B 
1083266 [efeB] NP_415538.1 deferrrochelatase, periplasmic 
4141846 [frwB] NP_418385.1 putative enzyme IIB component of PTS 
3091888 [yqgF] NP_417424.1 putative Holliday junction resolvase 
4123479 [priA] NP_418370.1 Primosome factor n' (replication factor Y) 
3913753 [atpC] NP_418187.1 F1 sector of membrane-bound ATP synthase, epsilon subunit 
3409497 [fis] NP_417727.1 global DNA-binding transcriptional dual regulator 
3389150 [tldD] NP_417711.1 putative peptidase 
1820025 [osmE] NP_416253.1 DNA-binding transcriptional activator 
4466494 [mgtA] NP_418663.1 magnesium transporter 
1776596 [ydiP] NP_416211.1 putative DNA-binding transcriptional regulator 
2337184 [gyrA] NP_416734.1 DNA gyrase (type II topoisomerase), subunit A 
3876758 [gyrB] YP_026241.1 DNA gyrase, subunit B 
138888 [gcd] NP_414666.1 glucose dehydrogenase 
2636621 [bamB] NP_417007.1 lipoprotein required for OM biogenesis, in BamABCDE complex 
3699608 [yhjV] NP_417996.1 putative transporter 
3809326 [rpmG] NP_418093.1 50S ribosomal subunit protein L33 
965164 [ycaI] NP_415433.4 inner membrane protein, ComEC family of competence proteins 
612445 [fes] NP_415117.1 enterobactin/ferric enterobactin esterase 
1615230 [ydeA] NP_416045.1 arabinose efflux transporter, arabinose-inducible 
1248080 [dhaM] NP_415716.4 fused predicted dihydroxyacetone-specific PTS enzymes: HPr component/EI component
2340916 [yfaL] NP_416736.1 adhesin 
49903 [folA] NP_414590.1 dihydrofolate reductase 
1447346 [tynA] NP_415904.3 tyramine oxidase, copper-requiring 
4611572 [yjjV] YP_026291.2 putative DNase 
2122831 [wcaI] NP_416554.1 putative glycosyl transferase 
2606930 [hyfG] NP_416982.1 hydrogenase 4, subunit 
3629733 [yhiJ] NP_417945.1 hypothetical protein 
2768099 [yfjR] NP_417123.1 CP4-57 prophage; predicted DNA-binding transcriptional regulator 
1207012 [stfP] NP_415672.1 e14 prophage; putative protein 
872573 [yliE] NP_415354.1 putative membrane-anchored cyclic-di-GMP phosphodiesterase 
807017 [ybhB] NP_415294.1 kinase inhibitor homolog, UPF0098 family 
358523 [cynT] NP_414873.1 carbonic anhydrase 
2316952 [rcsC] NP_416722.2 hybrid sensory kinase in two-component regulatory system with RcsB and YojN 
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986119 [ompF] NP_415449.1 outer membrane porin 1a (Ia;b;F) 
3560067 [glpD] NP_417884.1 sn-glycerol-3-phosphate dehydrogenase, aerobic, FAD/NAD(P)-binding 
2901374 [ygcE] NP_417256.1 putative kinase 
1188391 [phoQ] NP_415647.1 sensory histidine kinase in two-component regulatory system with PhoP 
98614 
[ftsW] NP_414631.1 lipid II flippase; integral membrane protein involved in stabilizing 
 FstZ ring during cell division 
1116242 [yceA] NP_415573.1 putative rhodanese-related sulfurtransferase 
1783059 [ppsA] NP_416217.1 phosphoenolpyruvate synthase 
255063 [pepD] NP_414772.1 aminoacyl-histidine dipeptidase (peptidase D) 
4489113 [idnR] NP_418685.1 DNA-binding transcriptional repressor, 5-gluconate-binding 
287866 [yagI] NP_414806.1 CP4-6 prophage; predicted DNA-binding transcriptional regulator 
1679516 [folM] NP_416123.1 dihydromonapterin reductase, NADPH-dependent; dihydrofolate reductase isozyme 
293443 [yagM] NP_414813.1 CP4-6 prophage; putative protein 
985125 [ompF] NP_415449.1 outer membrane porin 1a (Ia;b;F) 
4451774 [yjfF] NP_418652.2 putative sugar transporter subunit: membrane component of ABC superfamily 
1506749 [ydcP] NP_415952.2 putative peptidase 
3678090 [kdgK] NP_417983.2 ketodeoxygluconokinase 
3304283 [deaD] NP_417631.2 ATP-dependent RNA helicase 
4634900 
[creC] NP_418816.1 sensory histidine kinase in two-component regulatory system with CreB or PhoB, 
 regulator of the CreBC regulon 
2466906 [gtrB] NP_416852.1 CPS-53 (KpLE1) prophage; bactoprenol glucosyl transferase 
1012805 [pqiB] NP_415471.1 paraquat-inducible protein B 
1687656 [manA] NP_416130.3 mannose-6-phosphate isomerase 
4337036 [adiA] NP_418541.2 arginine decarboxylase 
2661303 [trmJ] NP_417027.1 tRNA mC32,mU32 2'-O-methyltransferase, SAM-dependent 
3472319 [rpsL] NP_417801.1 30S ribosomal subunit protein S12 
1273620 [ychO] NP_415738.2 putative invasin 
2049192 [yeeJ] NP_416485.4 putative adhesin 
801628 [ybhI] NP_415291.1 putative transporter 
613272 [ybdZ] YP_588441.1 stimulator of EntF adenylation activity, MbtH-like 
3558717 [glpG] YP_026220.1 rhomboid intramembrane serine protease 
971091 [ycbJ] NP_415439.1 hypothetical protein 
1453804 [paaC] NP_415908.1 ring 1,2-phenylacetyl-CoA epoxidase subunit 
3450113 [rplD] NP_417778.1 50S ribosomal subunit protein L4 
3338959 [yrbG] NP_417663.1 putative calcium/sodium:proton antiporter 
2470663 [yfdN] NP_416858.1 CPS-53 (KpLE1) prophage; putative protein 
3214292 [yqjH] NP_417541.1 putative siderophore interacting protein 
2126296 [gmd] NP_416557.1 GDP-D-mannose dehydratase, NAD(P)-binding 
3534319 [ompR] NP_417864.1 DNA-binding response regulator in two-component regulatory system with EnvZ 
2431182 [accD] NP_416819.1 acetyl-CoA carboxylase, beta (carboxyltransferase) subunit 
4600411 [yjjP] NP_418784.4 inner membrane protein, H-NS-repressed, DUF1212 family 
3813952 [rph] YP_001491547.1 defective ribonuclease PH 
3919572 [atpB] NP_418194.1 F0 sector of membrane-bound ATP synthase, subunit a 
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2143501 [yegE] NP_416571.1 putative diguanylate cyclase, GGDEF domain signaling protein 
2353576 
[glpC] NP_416746.1 anaerobic sn-glycerol-3-phosphate dehydrogenase, C subunit,  
4Fe-4S iron-sulfur cluster 
1131118 [flgD] NP_415593.1 flagellar hook assembly protein 
4377058 [frdD] NP_418575.1 fumarate reductase (anaerobic), membrane anchor subunit 
13782 [dnaK] NP_414555.1 chaperone Hsp70, co-chaperone with DnaJ 
1862103 [yeaD] NP_416294.4 hypothetical protein 
3471188 [fusA] NP_417799.1 protein chain elongation factor EF-G, GTP-binding 
801642 [ybhI] NP_415291.1 putative transporter 
3322744 [folP] NP_417644.4 7,8-dihydropteroate synthase 
1903785 [mntP] NP_416335.4 putative Mn(2+) efflux pump, mntR-regulated 
4443749 
[tamB] NP_418642.1 translocation and assembly module for autotransporter export, 
 inner membrane subunit 
4380036 [frdA] NP_418578.1 fumarate reductase (anaerobic) catalytic and NAD/flavoprotein subunit 
2666415 [hcaR] NP_417032.1 DNA-binding transcriptional activator of 3-phenylpropionic acid catabolism 
4100472 [kdgT] NP_418345.2 2-keto-3-deoxy-D-gluconate transporter 
3409403 [fis] NP_417727.1 global DNA-binding transcriptional dual regulator 
4090795 [frvA] NP_418336.1 putative enzyme IIA component of PTS 
1282377 [narG] NP_415742.1 nitrate reductase 1, alpha subunit 
1562385 
[dosP] NP_416006.4 oxygen sensor, c-di-GMP phosphodiesterase, heme-regulated; cold- and  
stationary phase-induced bioflim regulator 
377334 [frmB] NP_414889.1 S-formylglutathione hydrolase 
1710022 [nth] NP_416150.1 DNA glycosylase and apyrimidinic (AP) lyase (endonuclease III) 
3534074 [ompR] NP_417864.1 DNA-binding response regulator in two-component regulatory system with EnvZ 
850503 [ybiP] NP_415336.1 putative hydrolase, inner membrane 
2123896 [wcaH] NP_416555.2 GDP-mannose mannosyl hydrolase 
3932751 [rbsA] NP_418205.1 fused D-ribose transporter subunits of ABC superfamily: ATP-binding components 
3203536 [ttdR] NP_417532.1 transcriptional activator of ttdABT 
2809160 [mprA] NP_417169.1 DNA-binding transcriptional repressor of microcin B17 synthesis and multidrug efflux 
449164 [cyoB] NP_414965.1 cytochrome o ubiquinol oxidase subunit I 
714985 [ybfP] NP_415215.1 lipoprotein 
361229 [lacY] NP_414877.1 lactose permease 
2262723 [setB] NP_416675.1 lactose/glucose efflux system 
4388777 [rsgA] NP_418585.4 ribosome small subunit-dependent GTPase A 
2273314 [yejE] NP_416684.1 microcin C transporter YejABEF, permease subunit; ABC family 
537487 [ybbW] NP_415044.4 putative allantoin transporter 
1959288 [argS] NP_416390.1 arginyl-tRNA synthetase 
529386 [selU] NP_415036.1 tRNA 2-selenouridine synthase, selenophosphate-dependent 
1677229 [ydgH] NP_416121.1 hypothetical protein 
3472446 [rpsL] NP_417801.1 30S ribosomal subunit protein S12 
332568 [yahA] NP_414849.1 c-di-GMP-specific phosphodiesterase 
3915554 [atpG] NP_418189.1 F1 sector of membrane-bound ATP synthase, gamma subunit 
4064029 [yihP] NP_418313.4 putative transporter 
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4632681 [rob] NP_418813.1 right oriC-binding transcriptional activator, AraC family 
411349 [araJ] NP_414930.3 arabinose-inducible predicted transporter, MFS family 
3916825 [atpA] NP_418190.1 F1 sector of membrane-bound ATP synthase, alpha subunit 
995757 [ssuA] NP_415456.4 aliphatic sulfonate binding protein, SsuABC ABC transporter 
481922 [acrB] NP_414995.1 multidrug efflux system protein 
73799 [thiP] NP_414609.1 fused thiamin transporter subunits of ABC superfamily: membrane components 
4031406 [trkH] YP_026273.1 potassium transporter 
1078658 [putP] NP_415535.1 proline:sodium symporter 
2350765 
[glpA] NP_416744.1 sn-glycerol-3-phosphate dehydrogenase (anaerobic),  
large subunit, FAD/NAD(P)-binding 
2806082 [proX] NP_417165.1 glycine betaine transporter subunit 
770728 [cydA] NP_415261.2 cytochrome d terminal oxidase, subunit I 
2587372 [acrD] NP_416965.1 aminoglycoside/multidrug efflux system 
2789076 [lhgO] NP_417146.2 L-2-hydroxyglutarate oxidase 
503474 [fsr] NP_415012.1 putative fosmidomycin efflux system 
3542001 [yhgA] NP_417870.1 putative transposase 
450606 [cyoA] NP_414966.1 cytochrome o ubiquinol oxidase subunit II 
4297367 [fdhF] NP_418503.1 formate dehydrogenase-H, selenopolypeptide subunit 
3443175 [rpsE] NP_417762.1 30S ribosomal subunit protein S5 
1335816 [acnA] NP_415792.1 aconitate hydratase 1 
4417622 [ulaG] NP_418613.2 L-ascorbate 6-phosphate lactonase 
328784 [betT] NP_414848.1 choline transporter of high affinity 
1195500 [icd] NP_415654.1 e14 prophage; isocitrate dehydrogenase, specific for NADP+ 
813892 [uvrB] NP_415300.1 excinulease of nucleotide excision repair, DNA damage recognition component 
1679046 [folM] NP_416123.1 dihydromonapterin reductase, NADPH-dependent; dihydrofolate reductase isozyme 
3498207 [frlA] NP_417829.2 putative fructoselysine transporter 
4186886 [rpoC] NP_418415.1 RNA polymerase, beta prime subunit 
3078890 [tktA] YP_026188.1 transketolase 1, thiamin-binding 
3467132 [chiA] NP_417797.1 periplasmic endochitinase 
3031189 [idi] NP_417365.1 isopentenyl diphosphate isomerase 
2167265 [yegS] NP_416590.1 phosphatidylglycerol kinase, metal-dependent 
3915549 [atpG] NP_418189.1 F1 sector of membrane-bound ATP synthase, gamma subunit 
2419513 
[folX] NP_416806.1 D-erythro-7,8-dihydroneopterin triphosphate 2'-epimerase and 
 dihydroneopterin aldolase 
606258 [ybdK] NP_415113.1 weak gamma-glutamyl:cysteine ligase 
4243669 [malE] NP_418458.1 maltose transporter subunit 
745387 [nei] NP_415242.1 endonuclease VIII/ 5-formyluracil/5-hydroxymethyluracil DNA glycosylase 
1406960 [ydaN] NP_415858.1 putative Zn(II) transporter 
3920072 [atpB] NP_418194.1 F0 sector of membrane-bound ATP synthase, subunit a 
1035439 [hyaD] NP_415494.1 hydrogenase 1 maturation protease 
2112946 [wcaM] NP_416547.1 colanic acid biosynthesis protein 
258831 [phoE] NP_414776.1 outer membrane phosphoporin protein E 
4072916 [yihW] NP_418320.2 putative DNA-binding transcriptional regulator 
 98 
 
1898961 [yoaE] NP_416330.1 fused predicted membrane protein/conserved protein 
2809115 
[mprA] NP_417169.1 DNA-binding transcriptional repressor of microcin B17 synthesis and 
 multidrug efflux 
2610279 [hyfR] NP_416986.4 DNA-binding transcriptional activator, formate sensing 
3462354 [gspL] NP_417792.2 general secretory pathway component, cryptic 
3534564 [ompR] NP_417864.1 DNA-binding response regulator in two-component regulatory system with EnvZ 
107236 [lpxC] NP_414638.1 UDP-3-O-acyl N-acetylglucosamine deacetylase 
2279913 [yejH] NP_416689.1 putative ATP-dependent DNA or RNA helicase 
4429600 [ytfE] NP_418630.1 iron-sulfur cluster repair protein RIC 
2335231 [gyrA] NP_416734.1 DNA gyrase (type II topoisomerase), subunit A 
1555940 [ddpF] NP_416000.1 D,D-dipeptide permease system, ATP-binding component 
1585175 [ydeQ] NP_416019.1 putative fimbrial-like adhesin protein 
3720775 [glyS] NP_418016.1 glycine tRNA synthetase, beta subunit 
1011375 [pqiA] NP_415470.1 paraquat-inducible membrane protein A 
49899 [folA] NP_414590.1 dihydrofolate reductase 
2094391 [hisF] NP_416529.1 imidazole glycerol phosphate synthase, catalytic subunit with HisH 
2457798 [fadI] NP_416844.1 beta-ketoacyl-CoA thiolase, anaerobic, subunit 
2230720 [cdd] NP_416648.1 cytidine/deoxycytidine deaminase 
394141 [yaiV] NP_414909.2 putative DNA-binding transcriptional regulator 
134549 [yacL] NP_414661.2 hypothetical protein 
4003289 [pldA] NP_418265.1 outer membrane phospholipase A 
1923333 [holE] NP_416356.1 DNA polymerase III, theta subunit 
4365606 [aspA] NP_418562.4 aspartate ammonia-lyase 
1084229 [phoH] NP_415539.1 conserved protein with nucleoside triphosphate hydrolase domain 
3472510 [rpsL] NP_417801.1 30S ribosomal subunit protein S12 
985570 [ompF] NP_415449.1 outer membrane porin 1a (Ia;b;F) 
2960959 [ygdB] NP_417301.4 conserved protein, DUF2509 family 
976244 [mukB] NP_415444.1 chromosome condensin MukBEF, ATPase and DNA-binding subunit 
829692 [ybiH] NP_415317.4 putative DNA-binding transcriptional regulator 
541401 [glxK] NP_415047.1 glycerate kinase II 
2646542 [yfhM] NP_417015.1 hypothetical protein 
1939532 [yebA] NP_416370.2 putative peptidase 
1174851 [lolC] NP_415634.1 lipoprotein-releasing system transmembrane protein 
92536 [ftsI] NP_414626.1 transpeptidase involved in septal peptidoglycan synthesis (penicillin-binding protein 3) 
3409263 [dusB] NP_417726.1 tRNA-dihydrouridine synthase B 
3036024 [recJ] NP_417368.1 ssDNA exonuclease, 5' --> 3'-specific 
4275853 [soxR] NP_418487.1 DNA-binding transcriptional dual regulator, Fe-S center for redox-sensing 
154556 [htrE] NP_414681.1 putative outer membrane usher protein 
13794 [dnaK] NP_414555.1 chaperone Hsp70, co-chaperone with DnaJ 
2399892 [nuoE] NP_416788.1 NADH:ubiquinone oxidoreductase, chain E 
745740 [nei] NP_415242.1 endonuclease VIII/ 5-formyluracil/5-hydroxymethyluracil DNA glycosylase 
397655 [yaiW] NP_414912.1 putative lipoprotein required for swarming phenotype 
485556 [acrR] NP_414997.1 DNA-binding transcriptional repressor 
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142091 [can] NP_414668.1 carbonic anhydrase 
2154403 [mdtB] NP_416579.1 multidrug efflux system, subunit B 
3989990 [cyaA] NP_418250.1 adenylate cyclase 
1184515 [potA] NP_415644.1 polyamine transporter subunit 
1201235 [ymfJ] NP_415662.2 e14 prophage; putative protein 
3150978 [metC] NP_417481.1 cystathionine beta-lyase, PLP-dependent 
2389078 [nuoN] NP_416779.2 NADH:ubiquinone oxidoreductase, membrane subunit N 
474353 [tesB] NP_414986.1 acyl-CoA thioesterase II 
3921667 
[rsmG] NP_418196.1 16S rRNA m(7)G527 methyltransferase, SAM-dependent; 
 glucose-inhibited cell-division protein 
210256 [ldcC] NP_414728.1 lysine decarboxylase 2, constitutive 
3450112 [rplD] NP_417778.1 50S ribosomal subunit protein L4 
4220277 [arpA] NP_418441.1 ankyrin repeat protein 
3613466 [nikB] NP_417934.1 nickel transporter subunit 
485076 [acrR] NP_414997.1 DNA-binding transcriptional repressor 
2350107 [glpT] NP_416743.1 sn-glycerol-3-phosphate transporter 
2239959 [yeiB] NP_416657.1 putative inner membrane protein 
1893073 [pabB] NP_416326.1 aminodeoxychorismate synthase, subunit I 
1241402 [ldcA] NP_415710.1 murein tetrapeptide carboxypeptidase; LD-carboxypeptidase A 
1561985 
[dosP] NP_416006.4 oxygen sensor, c-di-GMP phosphodiesterase, heme-regulated; cold- and  
stationary phase-induced bioflim regulator 
2641863 
[rlmN] NP_417012.1 dual specificity 23S rRNA m(2)A2503, tRNA m(2)A37 methyltransferase,  
SAM-dependent 
1905255 [cspC] NP_416337.1 stress protein, member of the CspA-family 
4300211 [mdtO] NP_418505.2 membrane translocase (MDR) of MdtNOP efflux pump, PET family 
2872959 [cysN] NP_417231.1 sulfate adenylyltransferase, subunit 1 
2444787 [aroC] NP_416832.1 chorismate synthase 
1498815 [tehA] NP_415946.1 potassium-tellurite ethidium and proflavin transporter 
3620862 [rhsB] YP_026224.1 rhsB element core protein RshB 
3913929 [atpC] NP_418187.1 F1 sector of membrane-bound ATP synthase, epsilon subunit 
848953 [rhtA] NP_415334.1 threonine and homoserine efflux system 
1420210 [ydaV] NP_415878.1 Rac prophage; predicted DNA replication protein 
2022771 [dsrB] NP_416462.1 hypothetical protein 
2297193 
[napH] NP_416708.1 ferredoxin-type protein essential for electron transfer from  
ubiquinol to periplasmic nitrate reductase (NapAB) 
1656421 [ynfE] NP_416104.1 putative selenate reductase, periplasmic 
1707842 
[rsxD] NP_416147.1 electron transport complex protein required for the reduction of SoxR;  
predicted membrane protein 
4105296 [fieF] NP_418350.1 ferrous iron and zinc transporter 
268636 [perR] NP_414788.1 CP4-6 prophage; predicted DNA-binding transcriptional regulator 
2961948 [ppdA] NP_417303.1 hypothetical protein 
3469504 [fusA] NP_417799.1 protein chain elongation factor EF-G, GTP-binding 
75199 [thiB] NP_414610.1 thiamin transporter subunit 
2173807 [gatZ] NP_416598.1 D-tagatose 1,6-bisphosphate aldolase 2, subunit 
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774556 [tolQ] NP_415265.1 membrane spanning protein in TolA-TolQ-TolR complex 
4500355 [insG] NP_418698.1 IS4 transposase 
92376 [ftsI] NP_414626.1 transpeptidase involved in septal peptidoglycan synthesis (penicillin-binding protein 3) 
3415561 [acrF] NP_417732.1 multidrug efflux system protein 
1679652 
[folM] NP_416123.1 dihydromonapterin reductase, NADPH-dependent;  
dihydrofolate reductase isozyme 
2637716 [hisS] NP_417009.1 histidyl tRNA synthetase 
2236744 
[mglA] NP_416654.1 fused methyl-galactoside transporter subunits of ABC superfamily:  
ATP-binding components 
4102440 [cpxA] NP_418347.1 sensory histidine kinase in two-component regulatory system with CpxR 
1169484 [ycfS] NP_415631.1 L,D-transpeptidase linking Lpp to murein 
3469903 [fusA] NP_417799.1 protein chain elongation factor EF-G, GTP-binding 
3533176 [envZ] NP_417863.1 sensory histidine kinase in two-component regulatory system with OmpR 
2742061 [yfiB] NP_417096.1 putative positive effector of YfiN activity, OM lipoprotein 
2960869 [ygdB] NP_417301.4 conserved protein, DUF2509 family 
890551 [nfsA] NP_415372.1 nitroreductase A, NADPH-dependent, FMN-dependent 
1759220 [sufD] NP_416196.1 component of SufBCD Fe-S cluster assembly scaffold 
1838249 
[ynjE] NP_416271.4 IscS specificity factor for molybdenum cofactor biosynthesis;  
probable alternate MoaD transpersulfidase; weak thiosulfate:cyan> 
3753132 [aldB] NP_418045.4 aldehyde dehydrogenase B 
1931980 [edd] NP_416365.1 6-phosphogluconate dehydratase 
2650803 [sseA] NP_417016.4 3-mercaptopyruvate sulfurtransferase 
3075037 [yggP] YP_026187.1 putative dehydrogenase 
933793 [ftsK] NP_415410.1 DNA translocase at septal ring sorting daughter chromsomes 
953278 [focA] NP_415424.1 formate channel 
2404394 [lrhA] NP_416792.1 DNA-binding transcriptional repressor of flagellar, motility and chemotaxis genes 
1898621 [yoaE] NP_416330.1 fused predicted membrane protein/conserved protein 
2495951 [alaC] NP_416880.1 valine-pyruvate aminotransferase 3 
948708 [ycaN] NP_415420.1 putative DNA-binding transcriptional regulator 
3469722 [fusA] NP_417799.1 protein chain elongation factor EF-G, GTP-binding 
3409306 [fis] NP_417727.1 global DNA-binding transcriptional dual regulator 
3410103 [yhdJ] NP_417728.4 DNA adenine methyltransferase, SAM-dependent 
1110939 [opgH] NP_415567.1 membrane glycosyltransferase 
3409254 [dusB] NP_417726.1 tRNA-dihydrouridine synthase B 
1599053 [lsrR] NP_416029.1 lsr operon transcriptional repressor 
3471160 [fusA] NP_417799.1 protein chain elongation factor EF-G, GTP-binding 
2153637 [mdtB] NP_416579.1 multidrug efflux system, subunit B 
109508 [secA] NP_414640.1 preprotein translocase subunit, ATPase 
49910 [folA] NP_414590.1 dihydrofolate reductase 
2075231 [cbeA] NP_416508.1 CP4-44 prophage; cytoskeleton bundling-enhancing factor A; CbtA antitoxin 
3443741 [rplF] NP_417764.1 50S ribosomal subunit protein L6 
337435 [yahF] NP_414854.1 putative acyl-CoA synthetase with NAD(P)-binding domain and 
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 succinyl-CoA synthetase domain 
3472312 [rpsL] NP_417801.1 30S ribosomal subunit protein S12 
3745930 [lyxK] NP_418037.1 L-xylulose kinase 
1137330 [flgJ] NP_415599.1 muramidase 
806945 [ybhB] NP_415294.1 kinase inhibitor homolog, UPF0098 family 
1915668 [yebT] NP_416348.2 hypothetical protein 
3447952 [rplV] NP_417774.1 50S ribosomal subunit protein L22 
2591685 [ypfH] NP_416968.2 putative hydrolase 
2445967 [prmB] NP_416833.4 N5-glutamine methyltransferase 
4063212 [yihO] YP_026275.1 putative transporter 
129443 [yacH] NP_414659.1 hypothetical protein 
961696 [rpsA] NP_415431.1 30S ribosomal subunit protein S1 
1995253 [yecC] NP_416427.1 putative transporter subunit: ATP-binding component of ABC superfamily 
3644052 [rlmJ] NP_417956.1 23S rRNA m(6)A2030 methyltransferase, SAM-dependent 
3883850 [yidC] NP_418161.1 membrane protein insertase 
1946152 [yebC] NP_416378.1 conserved protein, UPF0082 family 
382780 [yaiP] NP_414897.1 putative glucosyltransferase 
2245341 [lysP] NP_416661.1 lysine transporter 
483101 [acrB] NP_414995.1 multidrug efflux system protein 
3162004 [parC] NP_417491.1 DNA topoisomerase IV, subunit A 
2393480 [nuoJ] NP_416783.1 NADH:ubiquinone oxidoreductase, membrane subunit J 
481611 [acrB] NP_414995.1 multidrug efflux system protein 
4597783 [yjjA] NP_418780.2 hypothetical protein 
149083 [panB] NP_414676.1 3-methyl-2-oxobutanoate hydroxymethyltransferase 
4052409 
[glnG] NP_418304.1 fused DNA-binding response regulator in two-component regulatory system with  
GlnL: response regulator/sigma54 interaction prot> 
1885529 [rnd] NP_416318.1 ribonuclease D 
309406 [ecpA] NP_414827.1 cryptic Mat fimbrillin gene 
3897779 [yieL] NP_418175.3 putative xylanase 
1195443 [icd] NP_415654.1 e14 prophage; isocitrate dehydrogenase, specific for NADP+ 
3533169 [envZ] NP_417863.1 sensory histidine kinase in two-component regulatory system with OmpR 
2531213 [cysK] NP_416909.1 cysteine synthase A, O-acetylserine sulfhydrolase A subunit 
1071165 [rutC] NP_415530.1 putative aminoacrylate deaminase, reactive intermediate detoxification 
3835938 [setC] NP_418115.1 putative arabinose efflux transporter 
890788 [nfsA] NP_415372.1 nitroreductase A, NADPH-dependent, FMN-dependent 
708293 [chiP] NP_415207.1 chitoporin, uptake of chitosugars 
2883688 [ygcB] NP_417241.1 R-loop helicase-annealase Cas3 needed for Cascade anti-viral activity 
2644248 
[pbpC] NP_417014.1 penicillin-binding protein PBP1C murein transglycosylase;  
inactive transpeptidase domain 
897129 [potI] NP_415378.1 putrescine transporter subunit: membrane component of ABC superfamily 
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Appendix C: Whole Genome Sequencing - Amplification Results 
 
Position  Length  Genes  Functions  
318621- 329114  10493  betA  Choline dehydrogenase,osmotic adaptation  
  betB  Betaine aldehyde dehydrogenase,osmotic 
adaptation  
  betI  Transcriptional repressor of bet genes  
389982- 400516  10584  insF1 & 
insE1  
Đnsertion sequence, phage ,transposon related  
  sbmA  Microcin B17 transporter  
  ddlA  Enzyme, murein sacculus peptidoglycan  
429408- 435825  6417  tsx  Transport of small molecules, nucleoside 
channel  
  ribD  Biosynthesis of cofactors,carriers: riboflavin  
  ribE  Riboflavin synthase, beta chain  
  nusB  RNA Synthesis, modification; transcription  
antitermination protein  
449835- 455514  5679  cyoA  Cytochrome o ubiquinol oxidase  
  ampG  Regulates beta lactamase synthesis  
479421- 486928  7507  acrB  Multidrug efflux system  
  acrA  Multidrug efflux system  
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  acrR  DNA binding transcriptional repressor  
557747- 566702  8955  sfmH  fimbrial-like adhesin protein  
  intD  Phage or prophage related  
 
Table C.1 All genes in the amplified regions of spiramycin strong selection strain-2 
 
Position  Length  Genes  Functions  
317334- 337838  20504  betA Choline dehydrogenase,osmotic 
adaptation 
  betB Betaine aldehyde 
dehydrogenase,osmotic adaptation 
  betI Transcriptional repressor of bet genes 
  betT  Transport of small molecules  
360880- 366178  5298  lacY  Electrochemical potential driven 
transporters  
  Lac Z  Beta-D-galactosidase, degredat,on of 
small molecules  
419295--436789  ~16000  proY  Proline permease transport protein  
  malZ  Maltodextri n glucosidase; degredation 
of small molecules :carbon compounds  
  queA  Queuosine biosynthesis; tRNA 
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ribosyltransferase isomerase  
  tgt  tRNA-guanine- transglycosylase; 
tRNA modification  
  secD  & secF  Peptide secretion,transport  
  tsx  Transport of small molecules, 
nucleoside channel  
432679- 433782  1103  ribD  Biosynthesis of cofactors, carriers: 
riboflavin  
433871- 434341  470  ribE  Riboflavin synthase, beta chain 
434361-434780  419  nusB  RNA Synthesis, modification; 
transcription  antitermination protein  
434858- 435835  977  thiL  Biosynthesis of cofactors, 
carriers:thiamin  
Thiamin-monophosphate kinase  
435813-436331  518  pgpA  phosphatidylglycerophosphatase  
447529-455694  8165  cyoB  Cytochrome o ubiquinol oxidase 
subunit I  
456002- 466261  10259  Cyo A  Cytochrome o ubiquinol oxidase 
subunit I I  
  ampG  Regulates beta lactamase synthesis  
  tig  
clpX  
Cell division factor  
Degredation of proteins,peptides  
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hupB  DNA binding transcriptional regulator  
456002-466261  10259  fadM  Long-chain acyl-coA thioesterase III 
Fatty acid degredation  
  queC  Queuosine biosynthesis  
478002-489731  11729  ylaC  Đnner membrane protein  
  hha  Protein-translation and modification  
Haemolysin expression modulating 
protein  
  tomB  Hha toxicity attenuator  
  acrB  Multidrug efflux system  
  acrA  Multidrug efflux system  
  acrR  DNA binding transcriptional repressor  
  mscK  Mechanosensitivity channel protein  
502700-503920   fsr  Fosmidomycin efflux system 
(putative) 
531675- 532157   allA  Ureidoglycolate hydrolase  
535810- 536688   glxR  Tartronate semialdehyde reductase  
558920-561523  2603  sfmD  Outer membrane protein ,export 
function (putative) 
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561559-562542  983  sfmH  Đnvolved in fimbrial assembly  
Putative fimbrial-like adhesion protein 
562553-563068  515  sfmF  putative fimbrial-like adhesin protein 
 
Table C.2 All genes in the amplified regions of amikacin weak selection strain-1 
 
Position  Length  Genes  Functions  
311848-
323033  
11185  insE1 & 
insF1  
Đnsertion sequence IS3A  
  ykgB  Đnner membrane protein  
390681-
397833  
7152  ins E1 & 
insF1  
Đnsertion sequence IS3B  
  sbmA  Microcin B17 transporter , drug/analog 
sensitivity  
560749- 
566449  
5700  sfmH  Fimbrial like adhesin protein 
Đnvolved in fimbrial assembly  
  sfmF  putative fimbrial-like adhesin protein 
569504-
574870  
5366  ybcL  Phage or prophage related  
  ylcH  Phage or prophage related 
  ybcN  Phage or prophage related 
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  ninE  Phage or prophage related 
  ybcO  Phage or prophage related 
572594-
572956  
 rusA  Degredation of DNA 
Phage or prophage related  
  ylcG  Phage or prophage related  
  quuD  Q-like transcriptional regulator, DLP12 
prophage 
579044-
584871  
5827  ybcW  Phage or prophage related  
  nohD  Bacteriophage DNA packaging protein 
Phage or prophage related  
  tfaD  Phage or prophage related  
  appY  DNA binding global transcriptional 
activator, DLP12 prophage  
  ompT  Outer membrane protein 3b  
 
Table C.3 All genes in the amplified regions of ciprofloxacin weak selection strain-2 
 
 
